Perioperative myocardial injury in non-cardiac surgery - incidence, patient characteristics, outcome, and possible strategies to improve outcome by Puelacher, Christian
1 
 
 
 
Perioperative Myocardial Injury in 
Non-cardiac Surgery - Incidence, 
Patient Characteristics, Outcome, and 
Possible Strategies to Improve 
Outcome 
 
 
 
Inaugural dissertation 
to be awarded the degree of  
Dr. sc. med. 
 
presented at 
the Faculty of Medicine  
of the University of Basel 
 
by 
Christian Puelacher 
from Basel, Switzerland / Innsbruck, Austria 
 
Basel, 2017 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch  
2 
 
 
 
 
 
Approved by the Faculty of Medicine  
On application of:  
 
Prof. Dr. med. Christian Müller (first supervisor)  
Prof. Dr. med. Mirjam Christ-Crain (second supervisor)  
Prof. Dr. med. Marco Valgimigli (external expert)  
 
Basel, 18.09.2017 
 
 
 
.…………….………………………………..  
Prof. Dr. Thomas C. Gasser, Dean 
  
3 
 
Table of contents 
Acknowledgements ............................................................................................................... 6 
Summary ............................................................................................................................... 8 
Deutsche Zusammenfassung ............................................................................................ 9 
Introduction ..........................................................................................................................10 
Myocardial injury after non-cardiac surgery .......................................................................11 
PMI Definition ...................................................................................................................11 
Gaps in research ..............................................................................................................12 
Incidence of PMI............................................................................................................12 
Preoperative risk stratification........................................................................................13 
Pathophysiology of PMI .................................................................................................14 
Potential strategies to improve outcome of PMI .............................................................14 
Rational for our study ....................................................................................................15 
Aims .....................................................................................................................................16 
Publications ..........................................................................................................................17 
I Perioperative myocardial infarction injury after non-cardiac surgery: incidence, and mortality 
and impact of cardiology consultation ...................................................................................17 
Abstract ............................................................................................................................18 
Clinical perspective ...........................................................................................................19 
Introduction .......................................................................................................................20 
Methods ............................................................................................................................21 
Results..............................................................................................................................26 
Discussion ........................................................................................................................29 
Conclusion ........................................................................................................................31 
Acknowledgements ...........................................................................................................32 
Tables ...............................................................................................................................34 
Figures..............................................................................................................................38 
Supplement ......................................................................................................................42 
4 
 
II Prediction of major cardiac events after vascular surgery ..................................................49 
Abstract ............................................................................................................................50 
Introduction .......................................................................................................................51 
Methods ............................................................................................................................52 
Results..............................................................................................................................55 
Discussion ........................................................................................................................57 
Conclusion ........................................................................................................................60 
Tables ...............................................................................................................................62 
Figures..............................................................................................................................70 
Supplement ......................................................................................................................75 
III Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac 
complications after non-cardiac surgery ...............................................................................76 
Abstract ............................................................................................................................77 
Introduction .......................................................................................................................78 
Methods ............................................................................................................................79 
Results..............................................................................................................................82 
Discussion ........................................................................................................................84 
Conclusion ........................................................................................................................87 
Tables ...............................................................................................................................90 
Figures..............................................................................................................................95 
Supplement ......................................................................................................................99 
Discussion and Outlook ...................................................................................................... 105 
Novel insights into PMI ................................................................................................... 105 
Incidence ..................................................................................................................... 105 
Outcome ..................................................................................................................... 105 
Subtypes ..................................................................................................................... 106 
Making use of hs-cTn preoperatively .............................................................................. 106 
Future planned directions of research ............................................................................. 107 
5 
 
Characterisation and pathophysiology of PMI .............................................................. 108 
Management strategies for PMI ................................................................................... 108 
Contributions by the PhD student ....................................................................................... 109 
Conclusion and closing remarks ......................................................................................... 111 
References ......................................................................................................................... 112 
Curriculum vitae ................................................................................................................. 125 
 
  
6 
 
Acknowledgements 
I am very grateful to everyone who supported me in accomplishing this PhD. 
I would like to thank all those involved in the scientific project, first and foremost my 
supervisor Prof. Christian Müller. He provided me with the opportunity to launch this huge 
project, counselled me and taught me skills that will be very valuable in my future career not 
only as researcher, but also as a physician. 
Likewise, I would like to thank Prof. Mirjam Christ-Crain for her ongoing support, not only with 
the research project but also through her efforts as head of the Department of Clinical 
Research to strengthen PhD education and clinical research at the University of Basel. I also 
wish to thank Prof. Marco Valgimigli for the time and effort he devoted to his role as external 
expert on the PhD committee. 
From the inception of this project, I have had the support of great researchers who reached 
across the borders of their disciplines to work with me on this interdisciplinary project. In this 
regard, I would like to thank Giovanna Lurati Buse and Manfred Seeberger for their support 
in the conception of the PMI-project. 
Many people from the Cardiovascular Research Institute also devoted a great deal of time 
and effort to this project: Michael Freese, Esther Seeberger, Raphael Sedlmayr, Jaqueline 
Espinola, Robert Polster, Helene Singeisen, Minh Dang, Sydney Corbière, Andres Zimmerli, 
Sanela Barac, Stella Marbot, Daniela Seeberger, Elena Appiani, Therese Rinderknecht, 
Cornelia Ganzoni, Lorraine Sazgary, Claudia Huck, and Kathrin Meissner. Several Masters 
students also contributed significantly to the project: Ekrem Temizel, Lukas Bock, Luca 
Osswald, Noemi Glarner, Christina Hollenstein and Saranya Thambipillai. 
Furthermore, I wish to thank the friends and colleagues who found time for discussions on 
the topic or methods and who helped me to grow significantly as a researcher: Raphael 
Twerenbold, Danielle Gualandro, Ursina Honegger, Stefanie Aeschbacher, Karin Wildi, Petra 
Hillinger, Max Wagener, Mario Kofler, Andreas Markl, Maria Rubini-Gimènez, Thomas 
Nestelberger, Jasper Boeddinghaus, Eckhard Mauermann, Jeanne du Fay de Lavallaz, 
Patrick Badertscher and Ivo Strebel. To all those friends I have not mentioned by name, I 
thank you very much for your friendship and the interest you showed in a topic that is arcane 
by any standard. 
I thank my family for their lifelong and ongoing support. I wish particularly to thank my 
mother, Cornelia Fischer, and my father, Wolfgang Puelacher, for raising me in an 
atmosphere of acceptance, for showing me the value of dedication, for inspiring and fostering 
my curiosity, teaching me always to pursue knowledge and, finally, assisting me to push the 
7 
 
boundaries of human knowledge. I also thank my sisters, Sylvana and Theresia, for being 
such great friends along the way, supporting me through both good and bad times, and for 
being honest with me about my strengths and flaws. 
Finally, I wish to thank one special person for her support over the last four years. From 
periods of unrestrained euphoria through the hardships of the long journey, to moments of 
soul searching; through long hours of work, through frenzies of activity as deadlines 
approached, Manon Geißler (and soon to be Puelacher) stood by my side and shared 
everything with me, unconditionally. Much has happened in this time, and I thank her for 
sharing all of it with me. 
 
  
8 
 
Summary 
The global volume of surgery is steadily increasing and surgical patients are becoming older 
and increasingly comorbid, making the perioperative setting a common challenge for 
physicians. Despite substantial improvements in surgical and anaesthesiological techniques, 
there is still a relevant risk of dying associated with non-cardiac surgery, with 30-day 
mortality rates ranging from 1 to 10% depending on the patient population. 
Major cardiac complications are believed to be a major contributor to this excessive mortality. 
In particular, perioperative myocardial injury (PMI) appears to be a major contributor and is 
potentially associated with one third of postoperative mortality. Initial study data have 
highlighted that PMI is difficult to diagnose, as typical symptoms of spontaneous acute 
myocardial infarction, especially ischemic chest pain, are only observed in <20% of all 
patients. 
In order to address important gaps in knowledge of PMI, we conducted my PhD project 
“Perioperative Myocardial Injury in Non-cardiac Surgery – Incidence, Patient Characteristics, 
Outcome and Possible Strategies to Improve Outcome“ (BASEL-PMI) at the University 
Hospital Basel. Its aim was to generate data within clinical routine to gain important insights 
into the incidence of PMI, its association with postoperative mortality, and to further 
characterise PMI. 
We were able to show that PMI is surprisingly common after non-cardiac surgery, occurring 
in 16% or in one in seven patients. With a mortality rate within 30 days of 10% and of 23% 
within one year, the associated mortality increased six-fold in comparison to patients without 
a PMI (1.6% at 30 days, 9.3% within one year), highlighting the importance of PMI as a 
perioperative complication. Nonetheless, due to their asymptomatic presentation (2/3 did not 
show any signs or symptoms), PMI are often missed in clinical routine. This lack of 
appreciation of a significant postoperative complication compromises the prognostic 
accuracy of preoperative scores used to assess the risk-benefit of surgery. 
In characterising PMI, we were able to identify two distinct subcategories of PMI, separating 
a “cardiac” subtype from an “extra-cardiac” subtype in which the heart is damaged by a 
systemic pathology such as severe sepsis. Furthermore, we were able to show that PMI is 
associated with an increased mortality independent of the ischemic symptoms or of whether 
the signs are present or not (8.7% vs 10.4%). 
Finally, we made our first tentative steps towards the hypothesis that systematic screening 
for PMI might improve outcome. 
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Deutsche Zusammenfassung 
Mit einer stetig zunehmenden Zahl an Operationen an immer älteren Patienten ist das 
perioperative Setting ein wichtiger Aspekt der modernen Medizin geworden. Trotz konstanter 
Entwicklung im Bereich der Anästhesie- sowie der chirurgischen Technik sind nicht-kardiale 
Operationen noch immer mit einem relevanten Risiko verbunden und je nach Kollektiv 
versterben 1-10% der Patienten innerhalb von 30 Tagen. 
Als ein wichtiger Faktor für diese Übersterblichkeit werden kardiale Komplikationen vermutet. 
Besonders perioperative Herzmuskelschädigungen (PMI) scheinen eine wichtige Rolle zu 
spielen und mit bis zu einem Drittel der Sterblichkeit assoziiert zu sein. In ersten Studien 
zeigte sich allerdings, dass die Diagnose solcher PMI schwierig ist, da das Kardinalsymptom 
des spontanen Herzinfarkts, die typischen Symptome wie v.a. Brustschmerz, in <20% der 
Patienten auftreten. 
Um bestehende grosse Wissenslücken über die wenig beschriebenen PMI zu adressieren, 
wurde mein PhD-Projekt „Perioperative Myocardial Injury in Non-cardiac Surgery - Incidence, 
Patient Characteristics, Outcome, and Possible Strategies to Improve Outcome“ (BASEL-
PMI) am Universitätsspital Basel initiiert. Ziel war es in der klinischen Routine Daten zu 
generieren über die Häufigkeit des Auftretens von PMI, ihren Zusammenhang mit der 
vermehrten postoperativen Sterblichkeit zu untersuchen und PMI besser zu beschreiben.  
In unsrer Studie zeigte sich, dass PMI erstaunlich häufig sind mit einer Inzidenz von 16%, 
also in einem von sieben Patienten auftritt. Mit einer Sterblichkeit von 10% in 30 Tagen und 
23% innerhalb eines Jahres, war die Übersterblichkeit dieser Patienten sehr hoch im 
Vergleich zu den Patienten ohne PMI (1.6% und 9.3%%), was die Bedeutung des PMI als 
perioperative Komplikation unterstreicht. Aufgrund ihrer meist symptomfreien Präsentation 
(2/3 zeigten keinerlei Symptome oder Zeichen), werden PMI in der klinischen Routine oft 
nicht erkannt. Durch die fehlende Erkennung dieser wichtigen postoperativen Komplikation 
ist die prognostische Wertigkeit präoperativer Risikoscores, welche zur Risiko-Nutzen-
Einschätzung chirurgischer Eingriffe genutzt werden, kompromittiert. 
Wir konnten zwei distinkte Subkategorien von PMI identifizieren, wobei wir „kardiale“ PMI 
abgrenzten von „extra-kardialen“ PMI, bei denen eine Erkrankung ausserhalb des Herzens 
als Hauptproblem das Herz in „Mitleidenschaft“ zieht. Eine zentrale Erkenntnis war weiteres, 
dass PMI unabhängig davon ob sie ischämietypische Symptome oder Zeichen zeigen oder 
nicht mit einer ähnlich erhöhten Mortalität (8.7% vs 10.4%) assoziiert waren. 
Bei der Analyse unsrer Daten konnten wir auch Hinweise darauf finden, dass das 
perioperative Screening nach PMI die Übersterblichkeit reduzieren könnte.  
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Introduction 
Worldwide, over 300 million major surgical procedures are performed annually, translating to 
one procedure for every 25 human beings1,2. In resource-rich countries like Switzerland, the 
incidence increases to as high as ~1 surgical procedure for every 10 citizens (~900.000 per 
year in Switzerland)1. Despite advances in all fields of medicine, there is still a significant risk 
of death related to major non-cardiac surgical procedures. The observed 30-day mortality 
depends on patient as well as procedural factors and ranges from 1% to 10%3–10.  
Perioperative major adverse cardiac events (MACE) and, in particular, perioperative 
myocardial injury (PMI) have only recently received scientific attention as a possible 
contributor to these perioperative deaths6,7,11.  
Perioperative myocardial injury differs in several aspects from spontaneously occurring acute 
myocardial infarction (AMI) presenting to the emergency department. One of the key 
differences seems to be that the vast majority of patients experiencing PMI do not show any 
typical ischemic symptoms, e.g. chest pain3,4,6,8–10,12. The reasons for this are not fully 
understood, but may include intense analgesia following surgery and possibly also different 
pathophysiological mechanisms underlying PMI11,13–16. Only in a minority of cases does PMI 
show any ischemic changes on the electrocardiogram (ECG), and such changes present in 
only 35% of patients7. As a consequence of this lack of typical symptoms and signs, most 
patients with PMI are currently not detected in routine clinical practice3,4.  
In spite of its silent manifestation, PMI is strongly associated with mortality. First studies 
estimated that PMI appeared to be a major contributor to 34–42% of all deaths within 30 
days of non-cardiac surgery3,7. It is important to note that the 30-day mortality of patients with 
PMI was similar for those who were asymptomatic and those who had ischemic symptoms 
(30-day mortality 12.6% in asymptomatic vs 9.8% in symptomatic patients, p=0.84)6. 
Symptoms and ECG changes are two important building blocks in the diagnosis of 
spontaneous AMI, according to current guidelines17, but the most important, and sine qua 
non feature is an elevated and dynamic value of cardiac troponin (cTn). Cardiac troponin T 
and I are cardiomyocyte-specific proteins which play an essential role in the contraction of 
the cardiac muscle18. Their function is to translate the excitation signal into contraction of the 
actin and myosin filaments. As they are only expressed in heart muscle cells, they are 
markers with high specificity for myocardial damage17,19–21. The introduction of high-sensitivity 
cTn (hs-cTn), assays able to measure cTn values in >50% of the population with adequate 
precision22, has been a significant improvement and has allowed the detection and 
quantification of myocardial injury at much lower thresholds17,23,24.  
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As the symptoms and the ECG lack reliability, international guidelines17,25,26 have begun to 
recommend routine monitoring of cTn in high-risk patients, both prior to and for 48–72 hours 
after major non-cardiac surgery. Implementing this monitoring as a systematic screening 
process appears necessary, as using only cTn measurements when deemed clinically 
indicated resulted in a three-fold lower rate of PMI detection when compared to systematic 
screening in a previous study4. 
Myocardial injury after non-cardiac surgery 
As a first step, the concept of “myocardial injury after non-cardiac surgery” (MINS) has been 
proposed for the perioperative setting7. In contrast to the diagnosis of spontaneous AMI, the 
diagnosis of MINS took into account the asymptomatic presentation of PMI and was based 
solely on cTn7,17.  
A conventional cTnT assay was used in the Vascular Events in Non-cardiac Surgery Patients 
Cohort Evaluation (VISION) study enrolling 15000 patients up to 2011. This study found that 
the 30-day mortality of patients was associated with postoperative peak cTn, ranging from 
1% at the lowest cTnT values (<10 ng/l) to 17% in the highest (>300 ng/l) group3. MINS was 
then defined as any postoperative cTnT value of ≥30ng/L. This resulted in an incidence of 
8% and an adjusted odds ratio (aOR) of 3.9 (95% confidence interval (95%CI) 2.9–5.3) for 
death within 30 days following MINS. 
Unfortunately, the definition “MINS” has a significant shortcoming as it relies only on 
postoperative measurements: it cannot distinguish between acute and chronic elevations of 
cTn. Cardiac troponin is known to be elevated in multiple chronic cardiac diseases, e.g. 
stable coronary artery disease, chronic heart failure, or atrial fibrillation27–29, and this would 
lead to a significant proportion of patients (especially in the aging comorbid surgical 
population) being classified as having MINS simply by reason of pre-existing chronic 
elevations. This was shown in a subgroup of the VISION population, where 22% had already 
had preoperative elevations in hs-cTnT, despite being a relatively healthy cohort (mean age 
65 years, 82% Revised Cardiac Risk Index ≤1)30. Such elevations have previously been 
shown to be independently associated with increased risk of death and MACE31. In actual 
fact, these patients did not experience an acute event that required any intervention and 
were hence at risk of overtreatment following an incorrect diagnosis of an acute disease. 
PMI Definition 
It is clear that a definition implementing this information about preoperative hs-cTn levels 
would be desirable to identify only acute events time-related to surgery, thus avoiding 
misclassification of chronically elevated levels. Such a definition could use delta values 
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instead of absolute postoperative levels. When diagnosing AMI in the non-surgical setting, 
absolute changes were shown to have a higher diagnostic accuracy when compared to 
relative changes32,33. In addition, from a scientific standpoint a definition using measurements 
pre- and postoperatively is essential if one is to be sure that an event is time-related to 
surgery and in order to draw conclusions about predisposing factors and potential 
pathophysiology of PMI. 
As a result of our limited understanding of PMI, no data on potential thresholds for absolute 
change of hs-cTn existed when this study commenced. The current definition for 
spontaneous AMI states that AMI should be diagnosed if a patient’s hs-cTn values show a 
dynamic profile and if the values at any time exceed the 99th percentile of values found in a 
healthy reference population17.  
We chose therefore to define PMI prospectively, and differently from MINS, as an absolute 
increase in hs-cTnT. We set the absolute increase needed for diagnosis of PMI to ≥14 ng/L, 
as 14 ng/L represents the 99th percentile of healthy individuals for the hs-cTnT assay22. In 
this way all PMIs would consistently fulfil the change as well as the absolute cTn criteria of 
the universal definition17. 
This decision was further corroborated by very recent data that became available in 2017, in 
which the MINS criteria were adapted after the introduction of hs-cTnT to the VISION study 
to include an additional criterion of an absolute change of ≥5 ng/L hs-cTnT for all 
postoperative values of hs-cTnT below 65 ng/L12. 
Gaps in research 
Incidence of PMI 
In the perioperative setting, myocardial infarction is believed to be a rare but dangerous 
event, occurring in 1%34–36 of patients undergoing non-cardiac surgery. From new study data 
we learned that PMI is often missed as a result of its commonly asymptomatic presentation 
and is much more common than currently seen in clinical routine. In observational studies 
PMI rates were reported to vary considerably, ranging from 6–73%3,5,30,37. This broad range 
of estimates stems from different study populations, different definitions of PMI and different 
cTn assays. In the most recent publication of the VISION study12, which enrolled patients 
older than 45 years, only postoperative measurements of conventional cTn were used to 
define MINS, and events accompanied by acute non-cardiac conditions were excluded. The 
multiple cut-off values defining an event were retrospectively chosen, with the lowest cut-off 
(at ≥20 ng/L) resulting in an incidence of PMI of 17.9%12. In a subset of the same study, the 
VISION-Biobank, hs-cTnT was measured pre- and postoperatively and PMI was defined as a 
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relative change to baseline of ≥85%, resulting in a markedly higher incidence of 22%30. In a 
study that included patients older than 60 years undergoing moderate to high-risk surgery, 
PMI was defined as elevations ≥60 ng/L in conventional cTnI, resulting in an incidence of 
19%5.  
This heterogeneity of results and the fact that nearly all were collected from observational 
study data underlined the need for a study using a prospective definition of PMI and a 
research setting integrated into routine clinical practice in order to generate an estimate that 
would be useful for clinical practice. 
Preoperative risk stratification 
Lack of appropriate detection of PMI and thereby overall major adverse cardiac events 
(MACE) in routine clinical practice also raises questions about the utility and accuracy of 
presently available clinical risk scores25,35,38,39. All currently recommended scores, e.g. the 
Revised Cardiac Risk Index (Lee score)35 or the recently developed American College of 
Surgeons National Surgical Quality Improvement Program (ACS NSQIP) surgical risk 
calculator39 were derived from studies without systematic perioperative screening, therefore 
capturing only symptomatic events or asymptomatic chance findings. This is particularly 
detrimental as both more accurate preoperative identification of high-risk patients and more 
precise and reliable early detection of MACE with initiation of therapy might have the 
potential to contribute to a reduction in perioperative mortality rates. 
One method with which to quantify the perioperative risk of MACE or death could be the use 
of hs-cTn. Conventional cTn assays have lacked prognostic accuracy, but the transition to 
hs-cTn offers potential for prediction, as shown by a study in which prognostic value was 
quantified by area under the receiver operating characteristics curve (AUC); this was 0.56 
(95%CI not given but including 0.5) for conventional cTnI and 0.69 (95%CI 0.60-0.78) using 
hs-cTnT40. Data from a vascular surgery cohort suggest that preoperative hs-cTnT 
measurements provide additional prognostic information to the Lee score in the prediction of 
AMI and death41. In a study enrolling non-cardiac surgery, hs-cTnT was also shown to be an 
independent predictor of MACE, including all-cause death31. Prognostic accuracy was 
moderate for the prediction of MACE (AUC 0.78), and superior to a commonly used risk 
score, the Lee score (AUC 0.68). Prognostic accuracy was also numerically higher than B-
type natriuretic peptide (AUC 0.71), an alternative biomarker in the perioperative setting31.  
To date, no study has evaluated hs-cTnI for the prediction of postoperative complications, 
and therefore no data on the comparison of both markers for preoperative risk stratification 
exist. It can be hypothesised that these markers might behave in like manner, but pilot 
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studies have also highlighted potential confounders of hs-cTn levels, which appear to be 
different for the cTnT and cTnI molecules42,43. 
Pathophysiology of PMI 
The predominant pathophysiology of PMI is currently unknown11,13,44,45. In patients presenting 
with spontaneous AMI, atherosclerotic plaque rupture and/or erosion with formation and 
often distal embolization of a thrombus, referred to as type I, is the dominant 
pathophysiological mechanism17. Initial pilot studies showed that only 50% of PMI may have 
been caused by plaque rupture and thus regarded as type I13,44,45. But as these studies 
recruited only a small minority of symptomatic PMI patients (~20%3), results might be biased 
towards inclusion of type I PMIs. 
It has been hypothesized that type II MI, characterized by a supply-demand mismatch of 
oxygen, and not type I MI, characterized by acute thrombotic coronary occlusion, might be 
the predominate mechanism of PMI11. This has been suggested as the perioperative setting 
is characterized by multiple factors associated with type II infarctions, e.g. imbalance of 
oxygen as a result of hypotension46–49, tachycardia16,50, hypoxemia51, or anaemia14, and 
potentially also sympathetic activation52 or hypothermia53.  
It is important to highlight the fact that acute extra-cardiac pathologies other than type II MI 
can affect the heart, as for example severe sepsis, which has been shown to cause 
cardiomyocyte injury without evidence of coronary artery disease54,55.  
Further characterization of the causes of PMI has enormous clinical consequences as type I 
AMI, for instance, has been shown to benefit from aggressive anticoagulation, platelet 
inhibition and early coronary revascularisation17,56, while these treatments may harm patients 
with PMI as a result of an increase in bleeding complications, especially detrimental in the 
perioperative period. 
Potential strategies to improve outcome of PMI 
Considering the worldwide volume of 300 million surgeries1,2, and assuming that a third of 
these are at elevated risk and that the incidence of PMI is 8%3,5,30,37, a total of eight million 
patients suffer a PMI every year, increasing their 30-day mortality almost four-fold. Strategies 
focusing on improving the outcome of PMI could therefore translate into considerable health 
gains, making high quality research on this issue extremely relevant. 
Related to our incomplete understanding of the incidence and pathophysiology underlying 
PMI, specific recommendations for treatment or prevention are currently lacking. This is a 
particular concern with regard to procedures and therapies associated with relevant peri-
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procedural risk such as coronary angiography and coronary revascularization, but also dual-
antiplatelet therapy inherently associated with increased bleeding. 
It is as yet unclear whether the use of current cardiovascular medication including statins, 
angiotensin-converting-enzyme-inhibitors/angiotensin II receptor-blockers, and beta-blockers 
might have the same beneficial effects on PMI as they do on AMI. Observational data from 
the neutral POISE study implied that use of acetylsalicylic acid or of statins was associated 
with a reduction in 30-day mortality (aOR 0.54, 95%CI 0.29 to 0.99 and aOR 0.26, 95%CI 
0.13 to 0.54 for statins)6. In a retrospective study in vascular patients, intensification of 
medical therapy according to the treatment recommendations for stable coronary artery 
disease57 was associated with a three-fold decrease in risk of major adverse cardiac events 
in one year in patients with a PMI58. In contrast, a small randomized controlled study of 70 
patients showed no that there were no benefits for one-year survival (17% vs 17%, p=1.0)59 
associated with transferring patients with cTnI-elevations to the cardiology ward rather than 
to the surgical ward. However, results from this study should be viewed with caution as it was 
carried out without a standard protocol of any interventions besides transfer to the cardiology 
ward and was based on highly unrealistic assumptions of the power calculation (absolute risk 
reduction in one-year mortality of 20%, from 35% to 15%)59.  
Related to the successes of preventive strategies in cardiac diseases in the non-surgical 
setting, research focusing on the prevention of PMI could be another very relevant area of 
study. In a pilot study, Ausset et al.60 showed that focusing on improving postoperative care 
to prevent PMI reduced one-year mortality from 8% to 2%. Measures taken were multiple, 
driven by a risk analysis followed by a complete overhaul of the processes in the 
researchers’ surgical ward60. As this was a single-centre open crossover study, a Hawthorne 
effect cannot be excluded. If we are to develop more targeted strategies, our understanding 
of the pathophysiology of PMI needs to be enhanced. 
Rationale of our study 
Overall, we saw a need for further research in the field of PMI that would have the potential 
to improve perioperative care. In the years since 2014 a growing number of studies has 
begun to add to our understanding of PMI, especially its incidence and outcome, but many 
questions remain unanswered. Data from this PhD project could make a significant 
contribution to addressing these questions. 
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Aims 
The primary aim of this project was to evaluate the incidence, outcome and characteristics of 
PMI in patients undergoing major non-cardiac surgery: 
1. Evaluate the incidence of PMI following major non-cardiac surgery  
2. Evaluate the association of PMI with all-cause death at 30 days and one year 
3. Describe subtypes of PMI and their association with all-cause mortality at 30 days 
and one year 
4. Evaluate the impact of PMI not fulfilling any additional criteria besides the troponin 
criterion necessary for diagnosis of spontaneous AMI17 
Further, the aims were to establish a large prospective cohort to address questions 
concerning the incidence of other MACE, evaluate current risk scores and describe the role 
of hs-cTn in preoperative risk scoring. 
5. Evaluate the incidence of MACE after non-cardiac surgery 
6. Evaluate established clinical risk scores for the detection of MACE 
7. Evaluate the prognostic utility of preoperative and postoperative hs-cTn in the 
prediction of all-cause death and MACE 
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Abstract 
Background: Perioperative myocardial injury (PMI) seems to be a contributor to mortality 
after non-cardiac surgery. As the vast majority of PMIs are asymptomatic, PMI usually is 
missed in the absence of systematic screening. 
Methods: We performed a prospective diagnostic study enrolling consecutive patients 
undergoing non-cardiac surgery that had a planned postoperative stay of ≥24 hours and 
were considered at increased cardiovascular risk. All patients received a systematic 
screening using serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) in 
clinical routine. PMI was defined as an absolute hs-cTnT increase of ≥14 ng/L from 
preoperative to postoperative measurements. Further, mortality was compared among 
patients with PMI not fulfilling additional criteria (ischemic symptoms, new ECG changes, or 
imaging evidence of loss of viable myocardium) required for the diagnosis of spontaneous 
acute myocardial infarction (AMI) versus those that did. 
Results: From 2014-2015 we included 2018 consecutive patients undergoing 2546 
surgeries. Patients were 42% female with a median age of 74 years. PMI occurred after 
397/2546 surgeries (16%, 95% confidence interval 14-17%) and was accompanied by typical 
chest pain in 24/397 patients (6%) and any ischemic symptoms in 72/397 (18%). Crude 30-
day-mortality was 8.9% (95%CI 5.7-12.0) in patients with PMI vs 1.5% (95%CI 0.9-2.0) in 
patients without PMI (p<0.001). Multivariable regression analysis showed an independent 
hazard ratio of 2.7 (95%CI 1.5-4.8) for 30-day mortality. The difference was retained at one-
year with mortality rates of 22.5% (95%CI 17.6-27.4) vs 9.3% (95%CI 7.9-10.7). 30-day 
mortality was comparable among patients with PMI not fulfilling any other of the additional 
criteria required for spontaneous AMI (280/397, 71%) versus those with at least one 
additional criterion (10.4%, 95%CI 6.7-15.7, vs 8.7%, 95%CI 4.2-16.7, p=0.684). 
Conclusion: PMI is a common complication following non-cardiac surgery and despite early 
detection during routine clinical screening, is associated with substantial short- and long-term 
mortality. Mortality seems comparable in patients with PMI not fulfilling any other of the 
additional criteria required for spontaneous AMI versus those that do.   
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Clinical perspective 
What is new? 
In patients with high cardiovascular risk, perioperative myocardial injury (PMI) detected and 
quantified by an acute increase in high-sensitivity cardiac troponin T plasma concentrations 
is a common complication after non-cardiac surgery occurring in one out of seven patients. 
Only 6% of patients with PMI experience typical chest pain, clearly indicating major 
differences to spontaneous myocardial infarction. PMI is associated with substantial 30-day 
and one-year mortality (9% and 22%), with similar mortality in patients with PMI not fulfilling 
the additional criteria for spontaneous myocardial infarction criteria versus those that do. 
What are the clinical implications? 
The high-risk criteria used in this study (age 65 years or older, or pre-existing atherosclerotic 
disease) deserve replication in clinical screening programs and research studies aiming at 
improving 30-day mortality. Major differences between PMI and spontaneous myocardial 
infarction mandate scrutiny in the individualized selection of treatment strategies following 
PMI.  
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Introduction 
Perioperative myocardial injury (PMI) has recently been identified as an important yet often 
undetected complication following non-cardiac surgery, strongly associated with 30-day-
mortality3,5,6,12,37. In contrast to spontaneous myocardial infarction (MI), PMI most commonly 
does not exhibit typical symptoms of myocardial ischemia such as chest pain, angina 
pectoris, or dyspnea, and is therefore missed in routine clinical practice in most institutions in 
the US and worldwide3,5,6,12,37. 
Considering more than 300 million surgeries are performed annually and demographic 
change is resulting in an increasing number of surgical patients with elevated cardiovascular 
risk, strategies improving the detection, treatment and outcome of PMI would seem to have 
an enormous potential to provide medical benefits. A missed diagnosis inevitably leads to a 
missed chance for treatment. Therefore, rapid and reliable detection of PMI is a crucial first 
step in efforts aiming to improve outcomes of this underappreciated perioperative 
complication. As electrocardiography (ECG) also has very low sensitivity7, the detection and 
quantification of acute cardiomyocyte injury by measuring cardiac troponin (cTn) is critical for 
the clinical diagnosis of PMI17,25.  
Recently, high-sensitivity cardiac troponin (hs-cTn) assays have been introduced into routine 
clinical care allowing for the first time the precise detection of acute cardiomyocyte injury due 
to PMI by using preoperative and postoperative hs-cTn measurements30. The differentiation 
between PMI and chronic elevations in hs-cTn due to chronic cardiac disorders appears 
paramount for the successful development of strategies to tackle the excess mortality 
associated with PMI while avoiding overtreatment.  
Based on recommendations to screen high-risk patients undergoing non-cardiac surgery for 
PMI17,25, our institution initiated a PMI screening program with a structured response system 
embedded within clinical routine. The aim of the present study was to 1) assess the 
incidence of PMI detected by a screening program implemented into clinical routine, which 
included both pre- AND postoperative measurements of hs-cTnT; 2) evaluate its association 
with 30-day and one-year-mortality.  
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Methods 
We adhered to the STROBE reporting guidelines, with further information found in the 
Supplement. 
Patients 
We included consecutive patients undergoing non-cardiac surgery at the University Hospital 
Basel, Switzerland, who were eligible for the institutional routine hs-cTn monitoring program 
and provided written general consent to registration in a dedicated prospective database. As 
the monitoring program was institutional routine, patients did not specifically consent to this 
standard of care. The study was approved by the local ethics committee (NCT02573532). 
Routine screening for PMI was implemented in October 2014 as part of the standard of care 
for high-risk patients undergoing inpatient non-cardiac surgery. Patients were screened if 
they had a planned hospital stay exceeding 24h after surgery and were considered at 
increased mortality-risk defined as ≥65 years of age, OR ≥45 years with history of coronary 
artery disease (CAD), peripheral arterial disease (PAD), or stroke. Plasma concentrations of 
hs-cTnT were measured within 30 days prior to surgery and on postoperative days 1 and 2, 
and later if clinically indicated. 
Screening was implemented for patients undergoing visceral, orthopedic, trauma, vascular, 
urologic, spinal, and thoracic surgical procedures. To improve compliance with the screening 
program, clinicians were alerted automatically of eligibility to the program based on the 
electronic health records. Serial high-sensitivity cardiac troponin T (hs-cTnT) measurements 
were ordered by the treating anaesthesiologist. Patients underwent hs-cTnT monitoring and 
were registered into the database multiple times if a minimum of 5 days had elapsed 
between procedures. 
Endpoints 
PMI was prospectively defined as an absolute increase in hs-cTnT of ≥14 ng/L above 
preoperative values (or between two postoperative values if the preoperative value was 
missing) within seven days of surgery. Based on findings from prior studies showing that 
asymptomatic elevations in cTn were also associated with increased short-term mortality3, 
we chose to not mandate specific symptoms or specific ECG changes into the definition of 
PMI. We used delta values instead of maximum postoperative levels to ensure that our 
definition reflected “acute” myocardial damage and was time-related to surgery, thus 
avoiding misclassification of chronically elevated levels. Chronic hs-cTn elevations are 
expected in a relevant amount of (surgical) patients61, and were previously shown to be 
independently associated with increased risk of death and major adverse cardiac events31. 
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We chose an absolute rather than a relative delta hs-cTnT level for the diagnosis of PMI, 
because absolute changes have shown higher diagnostic accuracy as compared to relative 
changes in the detection of acute MI in the non-operative setting32,33. The absolute increase 
of ≥14 ng/L was selected as 14 ng/L represents the 99th percentile of healthy individuals and 
thereby all PMIs invariably would fulfill the change as well as the absolute cTn criteria 
required for the diagnosis of spontaneous AMI17. 
PMI was centrally adjudicated by two independent experts based on all clinical information 
obtained during index hospitalization, including ECG, serial laboratory measurements 
including hs-cTnT and hemoglobin, monitoring of vital signs in the perioperative and 
intraoperative period, echocardiography, cardiac stress testing and coronary angiography, if 
performed. Two subtypes of PMI were classified: “extra-cardiac” in which a primarily extra-
cardiac disease such as severe sepsis, stroke, or pulmonary embolism triggered PMI, and 
“cardiac” for all other cases. In cases of disagreement between the two reviewers, 
consensus was sought and found by discussion with a third senior physician.  
We further characterized patients as to whether PMI also fulfilled at least one of the 
additional criteria required for the diagnosis of spontaneous AMI17. As all PMI necessarily 
fulfilled the cTn criteria, one or more of the following was required: presence of ischemic 
symptoms, new or presumed new significant ST-segment–T wave changes or new left 
bundle branch block, development of pathological Q waves in the ECG, imaging evidence of 
new loss of viable myocardium or new regional wall motion abnormality, identification of an 
intracoronary thrombus by angiography or autopsy17. The primary event-related prognostic 
endpoint was 30-day-mortality and one-year-mortality was the secondary prognostic 
endpoint. Deaths were classified as cardiovascular or non-cardiovascular according to recent 
guidelines62. Cardiovascular death included death due to acute myocardial infarction, sudden 
cardiac death, heart failure, stroke, cardiovascular procedure, cardiovascular hemorrhage 
(e.g. ruptured aortic aneurysm or dissection), and pulmonary embolism. All deaths were 
assumed to be cardiovascular in nature unless evidence of a non-cardiovascular cause was 
available. Non-cardiovascular death included all deaths due to a clearly documented non-
cardiac and non-vascular cause, such as respiratory failure (excluding cardiogenic 
pulmonary edema), infections/sepsis, neoplasm, trauma (including suicide and homicide), 
and surgical or gastrointestinal bleeding62. 
Procedures 
In case of an absolute increase in hs-cTnT of ≥14 ng/L above preoperative levels, structured 
response included assessing identified PMI patients for possible symptoms related to PMI 
and recording of a 12-lead ECG by study staff. In addition, a cardiology consultation request 
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was triggered electronically. In order to address the anticipated problem of insufficient 
staffing for the substantial number of additional cardiology consultations, particularly during 
the weekends, it was predefined at the start of the PMI-screening program that, in general, 
no cardiology consultations due to PMI would be performed during the weekends, on public 
holidays, whenever the cardiologist on call was busy with other, more urgent patients, and in 
case the patient was currently treated in the intensive care unit (ICU) at the time of PMI 
detection, as these patients already receive intense interdisciplinary care. Nonetheless, hs-
cTnT measurements were always available for the treating physician irrespective of the day 
of the week. All cardiologists providing cardiology consultation following PMI were 
continuously instructed in a predefined management scheme for PMI (Supplement Figure 
1). All treatment decisions regarding PMI were made by the treating surgeon in conjunction 
with the consulting cardiologist. 
We excluded patients who were incorrectly screened (<45 years, <24h hospital stay, surgery 
involving the heart), had their surgery cancelled, had cardiac surgery or myocardial infarction 
within 14 days before surgery, if only one hs-cTnT was measured, or if postoperative hs-
cTnT concentrations were elevated without a dynamic change (≥14 ng/L) AND preoperative 
“baseline” levels were missing. For the analysis addressing “30-day and one-year-mortality”, 
we included every patient only once at first enrollment (Supplement Figure 2).  
Data collection 
The Revised Cardiac Risk Index (RCRI) was calculated for all patients35. The cardiovascular 
risk of surgery was classified as proposed by the European Society of Cardiology (ESC) and 
the European Society of Anaesthesiology (ESA) (ESC/ESA-surgical risk)25. During the 
hospitalisation period, we recorded complications (sepsis, stroke, pulmonary embolism, 
pneumonia, postoperative delirium). Patient symptoms during PMI were extracted from the 
cardiology consultation report if available, or from electronic health records from the day first 
exceeding the hs-cTnT-delta threshold of ≥14 ng/L. Recommendations given in the 
cardiology consultations were collected from the electronic health records. 
During follow-up, patients were contacted after one year by mail or telephone, and local 
death registries checked. In case of suspicion of an outcome event, study personnel 
requested reports from the general practitioners, treating facilities or death registries. 
Patients lost to follow-up were censored at the last contact with the study team, a hospital or 
their general practitioner. 
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Hs-cTnT measurements 
Hs-cTnT was measured using an Elecsys (Roche Diagnostics) assay with limit of detection 
of 5ng/L, a 10% coefficient of variation at 13ng/L and the 99th percentile of a healthy 
reference population at 14 ng/L22. Hs-cTnT was measured in the 30-days preoperatively, with 
83% being measured within one day prior to surgery and 94% being measured within 3 days 
prior to surgery. 
Statistical analysis 
The incidence of PMI was calculated with 95% confidence intervals (95%CI) by the method 
proposed by Agresti63. PMI incidence was stratified by surgical disciplines, ESC/ESA surgical 
risk25, and postoperative stay on a regular ward or the ICU. The association of PMI with 
crude all-cause-mortality was evaluated using Kaplan-Meier curves and the log-rank test. To 
quantify the potential independent effect of preexisting chronic cardiomyocyte injury and 
acute perioperative cardiomyocyte injury (PMI), we included an analysis that stratified 
patients into four groups according to baseline troponin (low versus elevated) and PMI (acute 
perioperative elevation present or not). To determine adjusted hazard ratios (HR), we 
performed multivariable regression analyses with time to all-cause death as dependent 
variable. After evaluation of Schoenfeld residuals, a Cox Proportional Hazards model was 
chosen, and the HR for PMI and its subtypes were calculated adjusted for the predefined co-
variables age, non-elective surgery, RCRI, and complications during hospital stay (sepsis, 
stroke or pneumonia). Based on the number of events and the consensus of requiring 10 
events per independent variable compared in regression models, we were able to address 6 
variables64.  
Sensitivity analyses 
As reported in the flow chart, missing hs-cTnT measurements prevented definitive PMI 
adjudication in a subset of patients. We compared the baseline characteristics of these 
excluded patients with the analysed cohort (Supplement Table 1). 
To evaluate the validity of our outcome-analysis, we conducted sensitivity analyses and 
reran the 30-day mortality model a) including only cases with complete hs-cTnT 
measurements preoperative and in the first two postoperative days (“complete case model”), 
and b) censoring all patients if they had a repeat surgery leading to a PMI within 30 days at 
time of this later PMI (“later PMI censoring”). 
Hs-cTnT investigations 
To explore the association of absolute hs-cTnT increase and maximum postoperative hs-
cTnT level within seven days of surgery with 30-day mortality, we plotted 30-day mortality 
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according to increase in and maximum postoperative levels of hs-cTnT using a Loess-
function using 97.5% of data points.  
To evaluate the interaction of preoperative elevations in hs-cTnT ≥14 ng/L and PMI, we 
classified the patients according to PMI-status and presence of preoperative hs-cTnT 
elevation, and constructed Kaplan-Meier curves. 
Analysis was done using SPSS 22 and R 3.3 (“survival”, “survminer”).  
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Results 
Between October 2014 and November 2015, 2350 patients undergoing 2973 surgeries were 
screened for PMI. Of these, 2018 patients undergoing 2546 surgeries were eligible for this 
analysis (Supplement Figure 2). 
Incidence of PMI 
PMI occurred after 397/2546 surgeries (16%, 95%CI 14-17%). Patients with PMI had more 
cardiovascular comorbidities and consequently a higher RCRI, and a higher rate of non-
elective surgery (Table 1). The incidence of PMI increased with higher ESC/ESA-risk 
category of the surgical procedure from 9% in the lowest to 25% in the highest category 
(Supplement Table 2). PMI incidence differed in patients treated on the surgical ward, 
patients staying in the ICU for a short period, and patients with prolonged stay (≥2 days), with 
13% (95%CI 12-15), 19% (95%CI 15-23), and 56% (95%CI 46-65), respectively.  
The majority of patients with PMI, 325/397 (82%), did not show any ischemic symptoms, and 
chest pain was only present in 24/397 (6%). ECG findings suggestive of myocardial 
ischemia, especially ST-segment depression or T-wave inversion, were observed in 60/244 
(24%) of ECGs performed. Together with an additional 7 patients showing evidence of loss 
of viable myocardium on imaging, overall only 117/397 (29%) of patients fulfilled any of the 
additional criteria required for spontaneous AMI (Table 2). 
PMI subtypes 
342/397 PMI (86%, 95%CI 82-89) were classified as primarily “cardiac” and 55/397 (14%, 
95%CI 10-18) as primarily “extra-cardiac” subtypes. The causes for primarily “extra-cardiac” 
PMI were severe sepsis or uncontrolled infection in 40/55 patients. The proportion of “extra-
cardiac” PMI differed between patients treated on the surgical ward (9%, 95%-CI 6-12), 
patients staying in the ICU for a short period (16%, 95%CI 9-27), and patients with prolonged 
ICU stay ≥2 days (38%, 95%CI 26-51). 
Mortality associated with PMI 
Among 2018 patients eligible for analysis, 30-day follow-up was complete in 99.9% and one-
year follow-up in 99.6% of patients. Overall, 56/2018 patients (2.8%, 95%CI 2.1-3.6) died 
within 30 days; 23 (41%, 95%CI 29-54) due to cardiovascular and 33 (59%, 95%CI 46-71) 
due to non-cardiovascular causes.  One year after surgery, 224/2018 (11.2%, 95%CI 9.8-
12.7) patients died, 71 (32%, 95%CI 26-38) due to cardiovascular and 153 (68%, 95%CI 62-
74) due to non-cardiovascular causes. Data on the surgical course and hospital stay can be 
seen in Supplement Table 3, and number of cardiology consultations, cardiac imaging, and 
changes in cardiovascular medication can be seen in Supplement Table 4. 
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At 30 days, 28/285 (9.8%, 95%CI 6.8-14.0) patients with PMI versus 28/1733 (1.6%, 95%CI 
1.1-2.4, p<0.001) patients without PMI had died (Figure 1A). Cardiovascular death occurred 
in 14/285 (4.9%, 95%CI 2.8-8.2) patients with PMI compared to 9/1733 (0.5%, 95%CI 0.3-
1.0) patients without PMI. 
At one-year, 64/285 (22.5%, 95%CI 17.9-27.8) patients with PMI versus 160/1733 (9.3%, 
95%CI 8.0-10.8, p<0.001) patients without PMI had died (Figure 1B). Cardiovascular death 
occurred in 26/285 (9.1%, 95%CI 6.2-13.2) patients with PMI compared to 45/1733 (2.6%, 
95%CI 1.9-3.5) patients without PMI. 
In multivariate regression analysis, PMI was associated with a HR of 2.7 (95%CI 1.5-4.8, 
p=0.001) for 30-day-mortality, and a HR of 1.6 (95%CI 1.2-2.2, p=0.003) for one-year-
mortality (Table 3). 
PMI patients not fulfilling additional criteria required for spontaneous AMI had comparable 
30-day mortality and one-year mortality versus PMI patients fulfilling one or more of the 
additional criteria required for spontaneous AMI (10.4%, 95%CI 6.7-15.7 versus 8.7%, 
95%CI 4.2-16.7, p=0.684; and 22.1%, 95%CI 17.6-27.5, versus 29.1%, 95%CI 21.4-38.1, 
p=0.47, Figure 2).When analyzing different PMI subtypes, 30-day-mortality was 15/245 
(6.1%, 95%CI 3.6-10.0) versus 13/40 (32.5%, 95%CI 19.8-48.4, p<0.001, Figure 1C+D) in 
patients with PMI of “cardiac” and “extra-cardiac” subtype, respectively. In the group of 
patients with cardiac PMI, 60% of deaths within 30 days of surgery were cardiovascular, 
compared to 39% in patients with extra-cardiac subtype. 
At one year, 49/245 (20%, 95%CI 15-26) patients with a cardiac PMI versus 15/40 (38%, 
95%CI 24-53) patients with an extra-cardiac PMI had died. In the group of patients with 
cardiac PMI 43% of deaths within one year of surgery were cardiovascular, compared to 
33% in patients with extra-cardiac PMI. 
Results from the sensitivity analyses 
In the “complete case” sensitivity analysis (n=1829), including only cases with complete hs-
cTnT measurements preoperative and on the first two postoperative days, the adjusted HR 
for 30-day mortality of PMI was 2.8 (95%CI 1.6-5.2). 
In the “later PMI censoring” sensitivity analysis (n=2018) - censoring patients if they had a 
repeat surgery leading to a PMI - we found the 30-day mortality HR of PMI to be 3.2 (95%CI 
1.8-5.8). 
Association of hs-cTnT with 30-day-mortality 
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In our cohort, 1261 (51%) of all patients already had preoperatively hs-cTnT levels at or 
above the 99th percentile of 14 ng/L, with PMI patients showing an even higher proportion of 
80% (Table 4). 1936/2546 (76%) patients had an increase of hs-cTnT levels postoperative 
compared to preoperative values, with the median increase in the total population being 3 
ng/L (IQR 1-8, Table 4). Postoperatively, 1626/2546 (64%) patients had a postoperative level 
at or above the 99th percentile of 14 ng/L. 
When plotting 30-day mortality according to absolute hs-cTnT increase and maximum 
postoperative hs-cTnT levels, both plots indicated rather stable low mortality rates for very 
low delta (≤5 ng/L, 68% of the cohort) and low maximum values (≤10 ng/L, 25% of the 
cohort). While for maximum postoperative hs-cTnT values this was followed by a gradual 
near-linear increase, the association between hs-cTnT increase and mortality seemed to 
exhibit different slopes above 5 ng/L (Figure 3). 
When evaluating the interaction of preoperative hs-cTnT elevations and PMI, we found that 
PMI was associated with a worse outcome irrespective of preoperative values, but overall 
mortality was higher in patients with preexisting preoperative hs-cTnT elevations above the 
99th percentile (Figure 4).  
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Discussion 
This diagnostic study using central adjudication was embedded within a PMI-screening 
program implemented as part of routine clinical practice and aimed to contribute to a better 
understanding of PMI as an often neglected and underestimated complication following non-
cardiac surgery17,25. We report six major findings. 
First, the incidence of PMI following non-cardiac surgery detected during routine clinical 
screening in patients at increased cardiovascular risk is very high. One out of seven patients 
above the age of 65 years or with preexisting CAD, PAD, or stroke developed PMI. These 
findings extend and corroborate previous work on PMI, particularly the Vascular events In 
non-cardiac Surgery patIents cOhort evaluatioN (VISION) study3,5,12,30,37. The incidence of 
PMI observed in our study was comparable to that observed e.g. in VISION if using a 
comparable absolute hs-cTnT-delta criteria3,5,12,30,37. Differences in observed incidence rates 
found in several previous studies seem to relate to differences in the study populations, 
definitions of PMI, and the cTn-assays used3,5,12,30,37. The VISION study included patients 
older than 45 years (mean age 63 years) irrespective of preexisting CAD or PAD, and 
therefore at lower cardiovascular risk as compared to this study (median age 74 years). 
Accordingly, 30-day mortality in this study was twice that observed in VISION. In VISION,  
multiple cut-off values of maximum postoperative hs-cTnT levels defining an event were 
retrospectively chosen, with e.g. ≥20ng/L resulting in a PMI incidence of 17.9%12. In our 
cohort, median preoperative hs-cTnT concentration was 14 ng/L and the median maximum 
postoperative concentration in patients adjudicated to have PMI was 64ng/L. Regarding the 
definition of PMI, the high frequency of elevated hs-cTn plasma concentrations prior to 
surgery observed in this study (51%), VISION, and other studies clearly highlight the need for 
a definition that takes preoperative hs-cTn levels into consideration in order to avoid 
misclassification of chronic hs-cTn elevations as PMI5,12,30,65.  
Second, clinical presentation of PMI differed markedly from that of spontaneous AMI17. 
Among PMI patients, only 6% had typical chest pain, 18% had any ischemic symptoms, and 
29% fulfilled additional criteria required for spontaneous AMI beyond the increase in hs-
cTnT. These prospective observations corroborate that these acute events would in the vast 
majority have been missed in the absence of systematic screening3,5,6,12,37.  
Third, patients with PMI had six-times the 30-day-mortality observed in patients without PMI, 
despite the early detection within the clinical screening program. The excess mortality 
associated with PMI persisted up to one year.  
30-day mortality was comparable among patients with PMI not fulfilling any other of the 
additional criteria required for spontaneous AMI (ischemic symptoms, new ECG changes, 
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imaging evidence of loss of viable myocardium) versus those with at least one additional 
criterion. Similar observations were made in VISION, adding to the ongoing controversy of 
what criteria should be applied in the definition of perioperative myocardial infarction in 
addition to the documentation of acute cardiomyocyte injury.3,7,12,17,25,56 
Fourth, PMI associated with a primarily extra-cardiac disorder triggering cardiomyocyte 
injury such as severe sepsis has even worse prognosis with one out of three patients dying 
within 30 days. 
Fifth, acute cardiomyocyte injury occurring in the perioperative period (PMI) had additive and 
possibly amplifying detrimental effects on 30-day and one-year mortality on top of chronic 
cardiomyocyte injury due to various chronic cardiovascular disorders present prior to the 
operation. Accordingly, PMI was associated with increased mortality in patients presenting 
with low preoperative hs-cTnT concentrations as well as elevated preoperative hs-cTnT 
concentrations. In fact, the association between the amount of cardiomyocyte injury as 
quantified by hs-cTnT plasma concentration and mortality seemed to be continuous. 
Increasing absolute hs-cTnT deltas as well as increasing postoperative maximum hs-cTnT 
concentrations were associated with increasing mortality rates. While the association 
between postoperative maximum hs-cTnT concentrations and mortality seemed to be near 
linear in hs-cTnT concentrations above 10 ng/L, the association between absolute hs-cTnT 
deltas and mortality seemed biphasic above deltas of 5 ng/L. 
Sixth, after detailed review of all clinical information pertaining to the individual patient, 
coronary angiography was recommended by the cardiology consultant in only 10% of PMI 
patients. This highlights that the dominant pathophysiological mechanisms and the 
associated optimal management of patients with PMI is likely fundamentally different from 
that of patients with spontaneous MI. In the majority of patients with PMI cardiomyocyte 
injury seems to be caused by supply-demand mismatch due to hypotension, anemia, and 
tachycardia rather than plaque rupture11,13,56. However, these patients also had high 
cardiovascular mortality, and may benefit from intensification of medical treatment58. 
These findings extend and corroborate previous work on PMI and efforts aimed at improving 
outcomes after non-cardiac surgery3,5–7,12,65 The high incidence of PMI and the high mortality 
rate observed in this study suggests that the specific selection criteria used to identify high-
risk patients deserve to be replicated in future studies. Ideally, these should include a 
randomized controlled trial testing the effect of active surveillance combined with an active 
response protocol on clinical and economic outcomes.  
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Strengths 
Strengths of this study include the implementation of PMI screening in clinical routine, 
prospective assessment of symptoms possibly associated with PMI, central adjudication, use 
of hs-cTnT including pre-operative measurements to reliably distinguish PMI from chronic hs-
cTnT elevations from chronic cardiac disorders, long-term follow-up and very high 
completeness of follow-up (e.g. 99.9% at 30-days). 
Limitations 
The following limitations should be considered when interpreting these findings. First, there is 
no universally accepted definition of PMI. The absolute hs-cTnT change criteria used to 
define PMI in this study is at large arbitrary. While the hs-cTn cut-off criteria for spontaneous 
MI (99th percentile of healthy individuals) also is arbitrary, it is widely accepted and based on 
broad consensus. Our criterion for PMI is supported by recent data from VISION, but still 
requires approval by expert groups8. Second, hs-cTnT was measured routinely in the first 
two days after surgery, and afterwards only in case of clinical suspicion of MI. Therefore, a 
small number of asymptomatic PMIs occurring after the first days invariably were missed. 
Accordingly, our point estimates slightly underestimate the true incidence of PMI6,12. Third, 
the adjudication of PMI subtypes into “cardiac” and “extra-cardiac” PMI was largely based on 
clinical criteria, as the majority of patients did not undergo coronary angiography. 
Conclusion 
PMI is a common complication following non-cardiac surgery and despite early detection 
during routine clinical screening associated with substantial short- and long-term mortality. 
Mortality seems comparable in patients with PMI not fulfilling any other of the additional 
criteria required for spontaneous AMI versus those that do.  
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Tables 
Table 1 Baseline characteristics, shown for all cases and split for occurrence of 
Perioperative myocardial injuries (PMI), data shown as median [interquartile range limits] or 
counts (percentage); TIA = transient ischemic attack, RCRI = revised cardiac risk index; 
*comparisons were done using Mann-Whitney-U or Fisher’s exact test as appropriate. 
  
All patients 
n = 2546 
PMI 
n = 397 
No PMI 
n = 2149 
p-value* 
Age – years 74 [68-79] 76 [70-81] 73 [68-79] <0.001 
Sex – male 1468 (58%) 229 (58%) 1239 (58%) 0.519 
Coronary artery disease 735 (29%) 154 (39%) 581 (27%) <0.001 
Prior myocardial infarction 378 (15%) 89 (22%) 289 (13%) <0.001 
Chronic heart failure 322 (13%) 84 (21%) 238 (11%) <0.001 
Atrial fibrillation 415 (16%) 95 (24%) 320 (15%) <0.001 
Valvular heart disease 306 (12%) 72 (18%) 234 (11%) <0.001 
Peripheral artery disease 475 (19%) 106 (27%) 369 (17%) <0.001 
Prior stroke/TIA 254 (10%) 43 (11%) 211 (10%) 0.295 
Hypertension 1694 (67%) 292 (74%) 1402 (65%) 0.001 
Diabetes mellitus 621 (24%) 129 (32%) 492 (23%) <0.001 
Lung disease 408 (16%) 86 (22%) 322 (15%) 0.001 
Liver disease 166 (7%) 30 (8%) 136 (6%) 0.207 
Active tumor disease 674 (26%) 84 (21%) 590 (27%) 0.005 
RCRI class I 1106 (43%) 110 (28%) 996 (46%) 
<0.001 
RCRI class II 814 (32%) 130 (33%) 684 (32%) 
RCRI class III 419 (16%) 91 (23%) 328 (15%) 
RCRI class VI 207 (8%) 66 (17%) 141 (7%) 
Elective surgery 1772 (70%) 242 (61%) 1530 (71%) 
<0.001 Emergency surgery (≤24h) 314 (12%) 69 (17%) 245 (11%) 
Urgent surgery (>24h) 460 (18%) 86 (22%) 374 (17%) 
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Table 2 Clinical presentation, electrocardiographic (ECG) changes, and cardiac workup within seven days in patients experiencing a perioperative 
myocardial injury (PMI), shown also for different PMI subtypes; *rales, wheezing, or effusion; †pre and postoperative ECG available in 244 patients 
  
PMI 
n = 397 
PMI - cardiac 
n = 342 
PMI - non-cardiac 
n = 55 
Ischemic symptoms 
   
 
Typical Chest pain 24 (6%) 19 (6%) 5 (9%) 
 
Dyspnea 46 (12%) 39 (11%) 7 (13%) 
 
Atypical, but still possible ischemic symptoms 19 (5%) 18 (5%) 1 (2%) 
 
Any ischemic symptoms 72 (18%) 59 (17%) 13 (24%) 
Other signs and symptoms 
   
 
Palpitations 14 (4%)  13 (4%) 1 (2%) 
 
Edema 39 (10%) 35 (10%) 4 (7%) 
 
Nausea and vomiting 28 (7%) 25 (7%) 3 (5%) 
 
Lung auscultation positive* 38 (10%) 27 (8%) 11 (22%) 
(Presumably) new ECG findings† 
   
 
ST-segment elevation 5 (2%) 5 (2%) 0 (0%) 
 
ST-segment depression 29 (12%) 25 (11%) 4 (15%) 
 
T-wave inversion 27 (11%) 25 (11%) 2 (8%) 
 
New Q-waves 1 (0%) 1 (0%) 0 (0%) 
 
Any ischemic ECG changes 60 (24%) 54 (25%) 6 (23%) 
PMI fulfilling additional criteria for spontaneous AMI 117 (28%) 101 (27%) 16 (29%) 
 PMI not fulfilling criteria 280 (71%) 241 (70%) 39 (71%) 
 PMI fulfilling symptom or ECG change criteria 110 (28%) 94 (27%) 16 (29%) 
  PMI fulfilling only other additional criteria 7 (2%) 7 (2%) 0 (0%) 
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Table 3 Multivariate Cox proportional hazards model for 30-day and one-year-mortality after Perioperative myocardial injury (PMI), shown for 
models including PMI and including PMI split in cardiac and extra-cardiac subtype. Shown as hazard ratios (HR) with (95%CI); RCRI = revised 
cardiac risk index 
Model with PMI HR 30-day mortality p-value HR one-year mortality p-value 
PMI 2.73 (1.54-4.84) 0.001 1.58 (1.16-2.15) 0.003 
Age – years 1.06 (1.03-1.10) 0.001 1.05 (1.04-1.07) <0.001 
Non-elective surgery 3.07 (1.69-5.57) <0.001 1.42 (1.08-1.86) 0.013 
RCRI 1.34 (1.03-1.74) 0.031 1.57 (1.38-1.79) <0.001 
Sepsis 5.59 (2.99-10.47) <0.001 2.60 (1.67-4.04) <0.001 
Stroke 3.10 (1.16-8.32) 0.024 2.64 (1.34-5.20) 0.005 
Pneumonia 2.69 (1.28-5.63) 0.009 2.36 (1.54-3.63) <0.001 
Model with PMI subtypes         
PMI – cardiac 2.28 (1.19-4.36) 0.013 1.48 (1.07-2.06) 0.019 
PMI - non-cardiac 4.44 (1.85-10.63) 0.001 2.27 (1.20-4.27) 0.011 
Age -years 1.07 (1.03-1.10) <0.001 1.06 (1.04-1.07) <0.001 
Non-elective surgery 2.89 (1.57-5.31) 0.001 1.38 (1.05-1.83) 0.021 
RCRI 1.36 (1.04-1.77) 0.024 1.58 (1.39-1.80) <0.001 
Sepsis 4.45 (2.15-9.19) <0.001 2.33 (1.44-3.78) 0.001 
Stroke 2.37 (0.82-6.88) 0.113 2.38 (1.18-4.81) 0.016 
Pneumonia 2.85 (1.34-6.04) 0.006 2.37 (1.54-3.64) <0.001 
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Table 4 High-sensitivity cardiac troponin T (hs-cTnT) levels with interquartile range, number above the 99th percentile with percent and maximum 
perioperative delta shown for all patients, those with and without perioperative myocardial injury (PMI), as well as for subtypes cardiac and extra-
cardiac PMI 
  
preoperative 
hs-cTnT - ng/L 
preop values 
above  
99th - n (%) 
maximum 
postoperative 
hs-cTnT  - ng/L 
postop values 
above  
99th - n (%) 
maximum 
perioperative  
Δhs-cTnT  - ng/L 
Total cohort 14 (8-25) 1261 (51) 18 (11-33) 1626 (64) 3 (1-8) 
No PMI 12 (7-22) 957 (46) 15 (10-24) 1229 (57) 2 (0-5) 
PMI 28 (16-57) 304 (80) 64 (42-131) 397 (100) 25 (17-46) 
   PMI - cardiac 27 (15-51) 262 (79) 58 (41-109) 342 (100) 24 (17-43) 
   PMI - extra-cardiac 45 (18-95) 42 (84) 114 (53-175) 55 (100) 33 (19-83) 
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Figures 
Figure 1 Cumulative all-cause mortality within 30-days and one-year, shown for A+B) 
patients with (red) and without (black) perioperative myocardial injury (PMI), and C+D) 
patients according to PMI subtypes: cardiac PMI (dotted line), PMI associated with primarily 
non-cardiac disease such as e.g. severe sepsis (extra-cardiac PMI, dashed line), and 
patients without PMI (solid line) 
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Figure 2 Cumulative all-cause mortality within 30-days and one-year of patients with perioperative myocardial injury (PMI), split according to 
whether patients not fulfilling any of the additional criteria required for the diagnosis of spontaneous acute myocardial infarction besides the cardiac 
troponin criterion (ischemic symptoms, or ischemic sings on electrocardiography or on cardiac imaging) or if they fulfill at least one of the additional 
criteria 
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Figure 3 Association of absolute high-sensitivity cardiac troponin T (hs-cTnT) increase and maximum postoperative hs-cTnT level with 30-day 
mortality (black continuous line with 95%-confidence intervals in grey). A general linear fit is shown as red dashed line. As the association of 
absolute hs-cTnT increase with 30-day mortality might be affected by identifying and flagging PMI patients in clinical routine at hs-cTnT deltas of 
≥14 ng/L, this threshold was highlighted in the plot of absolute hs-cTnT increase (green dashed line) 
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Figure 4 Cumulative all-cause mortality within 30-days and one year of all patients stratified according to preoperative high-sensitivity cardiac 
troponin T (hs-cTnT) levels (above or below the 99th percentile) and occurrence of perioperative myocardial injury (PMI) after surgery (n=1937) 
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Supplement  
Outcome definitions 
Further baseline definitions 
Coronary artery disease was defined as history of coronary artery disease, history of acute 
myocardial infarction, finding of stenosis on coronary angiogram, or positive stress testing. 
Peripheral artery disease was defined as history of peripheral artery disease, known carotid 
stenosis, or arterial vascular surgery for aortic aneurysm. 
Stroke was defined as history of acute new focal neurological deficit judged by treating 
physicians to be of vascular cause lasting >24 hours 
Chronic heart failure was defined as history of congestive heart failure, left ventricular 
ejection fraction ≤40%, or diastolic dysfunction grade II or higher with elevated B-type 
natriuretic peptide irrespective of ejection fraction. 
Atrial fibrillation was defined as history of at least paroxysmal atrial fibrillation occurring more 
than once, or atrial fibrillation on preoperative ECG. 
Complications 
Sepsis was defined as clinical syndrome with presence of infection and clinical symptoms 
according to the International Sepsis Definitions Conference66. 
Stroke was defined as new focal neurological deficit judged by treating physicians to be of 
vascular cause lasting >24 hours. 
Pneumonia was collected from discharge diagnosis. If sepsis criteria were fulfilled at 
diagnosis, sepsis was adjudicated instead. 
Pulmonary embolism was collected from discharge diagnosis. 
Postoperative delirium was defined as delirium with onset within 7 days after surgery, as 
extracted from medical charts 
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Supplement Tables 
Supplement Table 1 Baseline characteristics of excluded patients compared to patients 
analysed. Data shown as median [interquartile range limits] or counts (percentage); TIA = 
transient ischemic attack, RCRI = revised cardiac risk index; *indicates significant differences 
compared to the cases analyzed assessed by Mann-Whitney-U or Fisher’s exact test as 
appropriate 
  
Cases analyzed 
n = 2546 
Only 1 hs-cTnT 
available 
n = 253 
No preoperative hs-
cTnT available and 
elevated post-op 
n = 48 
Age - years 74 [68-79] 72 [66-77]* 76 [70-81] 
Sex - male 1468 (58%) 147 (58%) 27 (56%) 
Coronary artery disease 735 (29%) 85 (34%) 21 (44%)* 
Prior myocardial infarction 378 (15%) 45 (18%) 9 (19%) 
Chronic heart failure 322 (13%) 29 (12%) 5 (10%) 
Atrial fibrillation 415 (16%) 35 (14%) 10 (21%) 
Valuvlar heart disease 306 (12%) 28 (11%) 7 (15%) 
Peripheral artery disease 475 (19%) 57 (23%) 5 (10%) 
Prior stroke/TIA 254 (10%) 26 (10%) 7 (15%) 
Hypertension 1694 (67%) 161 (64%) 30 (63%) 
Diabetes mellitus 621 (24%) 75 (30%) 14 (29%) 
Pneumopathy 408 (16%) 55 (22%)* 8 (17%) 
Hepathopathy 166 (7%) 20 (8%) 2 (4%) 
Active tumor disease 674 (26%) 67 (27%) 14 (29%) 
RCRI class I 1106 (43%) 82 (33%)* 18 (38%) 
RCRI class II 814 (32%) 97 (38%) 13 (27%) 
RCRI class III 419 (16%) 47 (19%) 7 (15%) 
RCRI class VI 207 (8%) 26 (10%) 10 (21%) 
Elective surgery 1772 (70%) 137 (54%)* 35 (73%) 
Emergency surgery (≤24h) 314 (12%) 59 (23%) 6 (13%) 
Urgent surgery (>24h) 460 (18%) 56 (22%) 7 (15%) 
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Supplement Table 2 Incidence of perioperative myocardial injuries (PMI) shown according 
to surgical specialty as well as procedure related surgical risk category25, data shown as 
percentage [95% confidence interval](absolute number of PMI/total cases group); ESC/ESA 
= European Society of Cardiology and the European Society of Anesthesiology 
 Incidence of 
PMI [95%CI] 
ESC/ESA surgical risk 
<1% 1-5% >5% 
All surgical specialities 
16% [14-17] 
(397/2546) 
9% [9-13] 
(79/833) 
17% [19-23] 
(248/1432) 
25% [28-39] 
(70/281) 
 
Orthopedic 
16% [12-20] 
(50/315) 
10% [6-18] 
(12/115) 
20% [15-26] 
(36/183) 
12% [2-36] 
(2/17) 
 
Trauma 
18% [15-22] 
(83/455) 
12% [8-17] 
(22/188) 
23% [19-29] 
(61/260) 
0% [0-41] 
(0/7) 
 
Spinal 
15% [11-19] 
(55/372) 
19% [6-44] 
(3/16) 
15% [11-19] 
(52/356) 
0% [0] 
(0/0) 
 
Thoracic 
24% [19-30] 
(53/219) 
8% [0-38] 
(1/12) 
22% [16-29] 
(38/174) 
42% [27-59] 
(14/33) 
 
Urologic 
9% [6-12] 
(37/432) 
6% [4-9] 
(19/319) 
12% [7-19] 
(12/104) 
67% [35-88] 
(6/9) 
 
Vascular 
20% [16-25] 
(66/322) 
21% [12-33] 
(12/58) 
15% [9-23] 
(14/96) 
24% [18-31] 
(40/168) 
 
Visceral 
11% [8-15] 
(38/346) 
6% [2-14] 
(5/84) 
12% [9-17] 
(27/221) 
15% [7-29] 
(6/41) 
 
Other 
19% [11-27] 
(15/85) 
12% [5-26] 
(5/41) 
21% [11-37] 
(8/38) 
33% [10-70] 
(2/6) 
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Supplement Table 3 Details on surgical course and hospital stay of patients (n=2018) with and without perioperative myocardial injury (PMI), 
further shown for different subtypes of PMI. Data shown as median [interquartile range limits] or counts (percentage); ICU = intensive care unit 
  
No PMI 
n = 1733 
PMI 
n = 285 
PMI - cardiac 
n = 245 
PMI - extra-cardiac 
n = 40 
Surgery duration - min 117 [75-170] 150 [85-215] 153 [90-227] 120 [70-195] 
ICU stay <2 days 220 (13%) 42 (15%) 34 (14%) 8 (20%) 
ICU stay ≥2 days 35 (2%) 42 (15%) 24 (10%) 18 (45%) 
Blood transfusion on day of surgery 73 (4%) 57 (20%) 44 (18%) 13 (33%) 
Blood transfusion <postop day 2  93 (5%) 69 (24%) 60 (24%) 9 (23%) 
Blood transfusion ≥postop day 2 299 (17%) 108 (38%) 87 (36%) 21 (53%) 
Complications during hospital stay         
 
Sepsis 46 (3%) 28 (10%) 9 (4%) 19 (48%) 
 
Stroke 13 (1%) 10 (4%) 5 (2%) 5 (13%) 
 
Pneumonia 43 (2%) 30 (11%) 21 (9%) 9 (23%) 
 
Pulmonary embolism 7 (0%) 7 (2%) 3 (1%) 4 (10%) 
 
Postoperative delirium 46 (3%) 34 (12%) 27 (11%) 7 (18%) 
Length of hospital stay - days 7 [4-10] 12 [8-18] 11 [8-17] 17 [9.5-24] 
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Supplement Table 4 Details on number of cardiology consultations, cardiac imaging, and 
changes in cardiovascular medication done in patients with and without perioperative 
myocardial injury (PMI) detected by routine screening. *for patients alive at discharge 
(n=2488) 
  
PMI 
n = 397 
No PMI 
n = 2149 
Postoperative cardiology consultation 206 (52%) 64 (3%) 
Cardiac workup within 30 days     
 
Coronary angiography 31 (8%) 11 (1%) 
 
Myocardial perfusion imaging 11 (3%) 6 (0%) 
 
Echocardiography 88 (22%) 93 (4%) 
New cardiovascular medication at discharge* 
  
 
Any of the below 105 (29%) 263 (12%) 
 
Acetyl salicylic acid 36 (10%) 48 (2%) 
 
P2Y12 inhibitors 20 (5%) 20 (1%) 
 
Statins 35 (10%) 34 (2%) 
 
Betablockers 30 (8%) 57 (3%) 
 
Renin-angiotensin-aldosteron-system inhibitors 32 (9%) 104 (5%) 
  Calcium channel blockers 17 (5%) 81 (4%) 
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Supplemental Figures 
Supplemental Figure 1 Predefined management scheme for cardiologists at the University 
Hospital Basel providing cardiology consultations following perioperative myocardial injuries 
(PMI), translated from German. All treatment decisions regarding PMI were made by the 
treating surgeon in conjunction with the consulting cardiologist 
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Supplement Figure 2 Study population selection. Patients could be included multiple times 
into the study, but where only considered at their first surgery for prognostic analyses; PMI = 
perioperative myocardial injury; cTn = cardiac troponin; AMI = acute myocardial infarction 
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Abstract 
Objective: Predicting cardiac events is essential to provide patients best medical care and to 
assess the risk-benefit-ratio of surgical procedures. The aim of our study was to evaluate the 
performance of the Revised Cardiac Risk Index (Lee) and the Vascular Study Group of New 
England Cardiac Risk Index (VSG) scores for the prediction of major cardiac events in 
unselected patients undergoing arterial surgery and to determine if the inclusion of additional 
risk factors improved their accuracy. 
Methods: 954 consecutive patients undergoing arterial vascular surgery were prospectively 
enrolled and Lee and VSG scores were calculated. Receiver Operating Characteristic curves 
for each cardiac risk score were constructed and the areas under the curve (AUC) 
compared. Two logistic regression models were done to determine new variables related to 
the occurrence of major cardiac events (myocardial infarction, heart failure, arrhythmias and 
cardiac arrest). 
Results: Cardiac events occurred in 120 (12.6%) patients. Both scores underestimated the 
rate of cardiac events across all risk strata. The VSG score had AUC of 0.63 (95%CI, 0.58-
0.68), which was higher than the AUC of the Lee score (0.58; 95%CI, 0.52-0.63; P=.03). 
Addition of preoperative anaemia significantly improved the accuracy of the Lee score to an 
AUC of 0.61 (95%CI, 0.58-0.67; P=.002), but not that of the VSG score. 
Conclusions: The Lee and VSG scores have low accuracy and underestimate the risk of 
major perioperative cardiac events in unselected patients undergoing vascular surgery. Lee 
score´s accuracy can be increased adding preoperative anemia. Underestimation of major 
cardiac complications may lead to incorrect risk-benefit assessments regarding the planned 
operation. 
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Introduction 
More than 300 million major surgeries are performed annually worldwide2. Patients submitted 
to arterial vascular surgery have an especially high risk of cardiac complications due to a 
high concomitant prevalence of atherosclerosis67,68. Cardiac events including myocardial 
infarction (MI), acute heart failure (AHF), and major arrhythmias after vascular surgery are a 
major concern for physicians and patients as they are associated with an increase in 
mortality, length of stay and cost11,69. Therefore, predicting cardiac events is essential to 
provide patients best medical care and also to assess the risk-benefit-ratio of surgical 
procedures. 
Although the use of clinical risk scores to predict postoperative cardiac events is 
recommended by most guidelines25,26,70, there is no specific recommendation for patients 
undergoing arterial vascular surgery. The Revised Cardiac Risk Index, developed by Lee et 
al (Lee score)35 is widely used to estimate cardiac risk for different procedures, but may 
underestimate risk in patients submitted to arterial vascular surgery71. The Vascular Study 
Group of New England Cardiac Risk Index (VSG) is a dedicated score to predict cardiac risk 
in patients submitted to vascular surgery, specifically developed for this population72. Lee and 
VSG scores were developed in selected populations, ie. undergoing elective surgery and 
specific types of procedures. Their accuracy in real-world unselected patients undergoing 
vascular surgery is largely unknown.  
The aim of our study was to evaluate the performance of the Lee and the VSG scores for the 
prediction of major cardiac events in unselected patients undergoing arterial surgery. Our 
secondary aim was to determine if the inclusion of additional risk factors improves their 
accuracy.   
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Methods 
Study design and overview 
The GREAT (Global Research on Acute Conditions Team) Perioperative Initiative is an 
ongoing prospective international collaboration aiming to improve cardiovascular 
perioperative care. For this analysis, individual patient data from two prospective cohorts 
were pooled: 1) from September 2012 to March 2016, we included consecutive patients 
undergoing arterial vascular surgery at the Clinics Hospital, University of São Paulo Medical 
School, Brazil, for whom a preoperative cardiologic consultation was requested. In São Paulo 
there is a special routine for patients undergoing arterial surgery, in which patients are 
systematically seen by cardiologists before surgery. 2) from October 2014 until October 
2015, consecutive patients undergoing vascular surgery at Basel University Hospital, 
Switzerland were included. The University Hospital of Basel implements a perioperative 
troponin screening in clinical routine since October 2014 in patients at high perioperative 
cardiovascular risk undergoing major non-cardiac surgery. All screened patients are 
registered in a dedicated prospective database. The protocol was approved by the local 
ethics committees and informed consent was not required.  
Patients 
We included patients undergoing all vascular arterial surgeries: open or endovascular (for 
aorta, peripheral artery, visceral arteries and carotid artery diseases and amputations due to 
limb ischemia), emergent, urgent or elective. Patients who were not submitted to arterial 
surgery or patients who underwent renal transplantation were excluded (Supplement Figure I 
in the supplemental content)  
Preoperative assessment and scores 
Patients were submitted to clinical evaluation, and Lee35 and VSG72 scores were applied 
(Figures I and II). The Lee score is routinely used for preoperative evaluation in clinical 
practice and was taken into account by the attending physician to guide perioperative 
management according to local guidelines25,26. Preoperative additional cardiac tests were 
done at discretion of the attending physician, following local guidelines25,26. 
Previous coronary artery disease (CAD) was considered if the patient had history of 
myocardial infarction (MI), angina pectoris or myocardial revascularization (CABG or PCI), or 
evidence of CAD in myocardial perfusion imaging (presence of fixed or reversible perfusion 
defects) or coronary angiography. Preoperative chronic heart failure (CHF) was considered if 
there were: clinical symptoms consistent with CHF regardless of left ventricle ejection 
fraction (LVEF), LVEF lower than 50% assessed by echocardiography or LVEF lower than 
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45% assessed by GATED SPECT obtained during myocardial perfusion imaging. In cases 
with diagnostic uncertainty, BNP or NT-proBNP levels were used if available. In patients with 
CHF diagnosis, NYHA functional class was obtained by cardiologists. Smoking status 
included current and prior smokers. Anaemia was diagnosed according to World Health 
Organization (WHO) criteria as hemoglobin levels below 12g/dl for women and below 13g/dl 
for men73.  
Perioperative Surveillance  
Perioperative surveillance included serial measurements of high-sensitivity cardiac Troponin 
T (hs-cTnT; Roche Diagnostics) once daily up to the second or third day after surgery, and 
12-lead electrocardiogram (ECG) daily in São Paulo and in case of hs-cTnT elevations in 
Basel. Additional ECG and hs-TnT measurements were performed whenever clinically 
indicated. Hs-cTnT was selected due to its improved diagnostic accuracy compared to other 
less sensitive cTn assays in the diagnosis of MI23. Patients were followed-up until hospital 
discharge.  
Clinical endpoints 
The primary endpoint was a composite of cardiac events, including perioperative myocardial 
infarction (MI), acute heart failure (AHF), clinically relevant arrhythmias and cardiac arrest 
until hospital discharge. All endpoints were adjudicated by two cardiologists. MI was 
diagnosed according to the Third Universal Definition of Myocardial Infarction17. AHF was 
diagnosed by the attending physician, by clinical symptoms, physical examination, chest x-
ray,BNP or NT-proBNP blood concentrations, and echocardiography74. Arrhythmias (atrial 
fibrillation/flutter, supraventricular tachycardia, ventricular tachycardia) were considered 
clinically significant if requiring drug therapy or electrical cardioversion. We chose this 
combined endpoint because it is the same endpoint used in the derivation of the Lee and 
VSG scores35,72.  
Statistical analysis 
Categorical variables are presented as frequencies (percentages) and were compared by χ-
square test or Fisher’s test, as appropriate. Numerical variables are reported as medians and 
interquartile range (IQR) and were compared by Mann-Whitney test. We evaluated the 
incidence of the combined endpoint in each category of each cardiac risk score. Confidence 
intervals for incidence of the endpoint were calculated using the standard formula. 
For our primary analysis, comparison of the risk scores, Receiver Operating Characteristic 
(ROC) curves for each cardiac risk score were constructed and the areas under the curve 
(AUC) compared by the method by DeLong75. Confidence intervals were constructed using 
54 
 
bootstrap. Sensitivity analysis for the AUC of both scores was done by excluding patients 
undergoing emergency or urgent surgeries. A post-hoc subgroup analysis of patients 
undergoing open or endovascular procedures was also performed. 
For our secondary analysis, to determine new variables independently related to the 
occurrence of cardiac events after surgery, two binary logistic regression models for each 
score were created including the scores and variables preselected by literature research 
(urgency, anaemia, preoperative medication use)25,26,35,38,70,72,76–79. As power estimation for 
our regression analysis, we chose to include a maximum number of covariables of one 
variable per ten events80. The same variables were included in both models, except for 
variables that were already part of the respective score, such as “type of surgery” in Lee 
score or “smoking status” in VSG score. Variables with a p-value <0.05 were then added to 
the scores and ROC curves of the scores including the new variables were constructed. 
AUCs of the modified scores and of the original scores were compared. 
P-values of less than 0.05 were considered to indicate statistical significance. Analyses were 
performed using SPSS 22 (IBM Co., NY, USA) and R software (Version 3.1.3, “pROC”81).   
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Results 
One thousand two hundred and twenty-six patients were evaluated, and 272 were excluded 
(Supplement Figure I in the supplemental content). Baseline characteristics and outcome of 
patients divided by hospital are shown in Table I. Baseline characteristics of 954 patients 
included with and without a cardiac event are shown in Table II. About one-third of patients 
underwent aortic aneurism repair, one-third lower extremity bypass or angioplasty and one-
fourth carotid procedures (Table III). Overall, 71% of patients underwent elective surgery, 
24% urgent and 5% emergent (within one day) surgeries.  
The primary endpoint of major cardiac events occurred in 120 (12.6%) patients. MI occurred 
in 66 (6.9%) patients, AHF in 46 (4.8%), clinically relevant arrhythmias in 24 (2.5%) and 
cardiac arrest in 13 (1.4%). The primary endpoint and MI incidence according to type of 
surgery is shown in Table III. 
As for postoperative surveillance, 5% of patients did not have postoperative troponin values 
available. Median length of hospital stay was five days (IQR 3-8). Seventy-one patients died 
in-hospital, resulting in an in-hospital all-cause mortality rate of 7.4%. 
Accuracy of established scores 
The incidence of the primary endpoint according to risk strata for each cardiac risk score is 
shown in Table IV and Figure III. The observed risk was substantially higher than that 
predicted by both scores, particularly in the lower strata. Prognostic accuracy as quantified 
by the AUC was low for both scores. ROC curves for Lee (AUC 0.58; 95%CI, 0.52-0.63) and 
VSG scores (AUC 0.63; 95%CI, 0.58-0.68) are shown in Figure IV. Comparison of the two 
AUC showed the VSG score to be superior to the Lee score (p=0.03). Sensitivity analysis 
showed similar results when we analyzed only the 620 patients (78 events, 12.6%) submitted 
to elective surgery: AUC of Lee score was 0.58 (95%CI, 0.51-0.65) and for VSG score was 
0.61 (95%CI, 0.55-0.67).  
Subgroup analysis of the type of approach (endovascular vs. open) did not show different 
accuracy of the scores: in patients submitted to endovascular procedures, AUC for Lee score 
was 0.56 (95%CI, 0.48-0.65) and for the VSG score was 0.64 (95%CI, 0.56-0.72) and, in 
patients submitted to open procedures, AUC for Lee score was 0.59 (95%CI, 0.52-0.66) and 
for the VSG score was 0.62 (95%CI, 0.56–0.68).  
Additional variables related to cardiac events 
Independent risk factors for the primary endpoint in the Lee score model (Table V.A) were: 
smoking (OR 1.8 95%CI 1.1-3.1; P=.03), preoperative anaemia (OR 2.0 95%CI, 1.3-3.0; 
p=0.001) and the Lee score itself (OR 1.3 95%CI, 1.0-1.5; p=0.04). In the VSG score model 
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(Table V.B), besides the VSG score (OR 1.2 95%CI, 1.1-1.4; p<.001), only anaemia 
remained as an independent predictor of the primary endpoint (OR 1.9 95%CI, 1.3-2.9; 
p=0.002). 
Adding anaemia improved the accuracy for prediction of primary endpoint only for the Lee 
score (Figure V): AUC for Lee score plus anaemia of 0.61 (95%CI 0.58-0.67; p=0.002 for 
comparison with original Lee score). This power-up effect was not significant for the VSG 
score: AUC for VSG plus anaemia was 0.65 (95%CI, 0.60-0.70; P=.10 for comparison with 
original VSG score). AUC of the Lee score plus anaemia and VSG score were similar (0.61 
vs. 0.63, respectively; p=0.50). Adding smoking to the Lee score did not improved accuracy 
measured by AUC (AUC for Lee score plus smoking was 0.59; 95%CI, 0.54-0.65).  
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Discussion 
In this collaborative prospective observational study, we aimed to evaluate the performance 
of two preoperative risk scores in unselected patients undergoing vascular surgery. We 
report three major findings. First, both scores substantially underestimated the rate of major 
cardiac events across all risk strata. Second, both scores had low accuracy in a real world 
setting of unselected patients undergoing vascular surgery, but VSG score provided better 
discrimination compared to Lee score. Third, addition of anaemia to the Lee score improved 
its accuracy and equalized it to VSG in this sample. 
In a real world unselected population, both Lee and VSG scores substantially underestimate 
cardiac risk. This is of major concern, as underestimation of major cardiac complications 
including MI, AHF, cardiac arrest, major arrhythmias and cardiac death invariably leads to 
incorrect risk-benefit assessments by physicians and patients regarding the planned 
operation.  
We have found a much higher overall cardiac event rate than observed in the derivation 
cohorts (12.6% vs 6.3% for VSG and 2-2.5% for Lee)35,72. Vascular patients have previously 
been shown to have a higher risk of cardiac complications77, therefore it was expected that 
our overall cardiac event rate would be higher than Lee et al.’s original paper. However, the 
finding of much higher cardiac event rate than VSG cohort was unexpected. There are some 
possible explanations for this finding. 
First, surveillance and diagnostic criteria of MI were different among studies. In our cohort, 
we performed routine surveillance with hs-cTnT measurements after surgery due to its 
diagnostic superiority as compared to less sensitive assays23, which allowed us to identify the 
vast majority of MIs in the first days. As in more than 50% of cases MIs patients do not 
complain of chest pain6,13, most MIs will be missed without routine screening4. In a recent 
registry that included 88,791 patients submitted to non-emergent vascular operations the 
overall incidence of MI was 1.6%76. Previous studies also reported lower overall procedure 
specific perioperative MI rates than ours, most likely due to better surveillance in our 
prospective study38,78. As there is no specific universal definition for MI after non-cardiac 
surgery, the difference in incidence of MI in several studies depends on the diagnostic 
criteria and the cTn assay used17.  
Second, differences between cohorts need to be considered, such as baseline 
characteristics of the included patients and type of surgery. Overall, our population was older 
and had a higher prevalence of known CAD and CHF, consistent with current daily clinical 
practice. Forty percent of VSG score´s original population had a Lee score below class II, 
whereas only 14% of our population had a Lee score below class II72. The type of surgery is 
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also a major issue. Our inclusion criteria were broader than those from the VSG cohort which 
just included non-emergent carotid endarterectomy, open or endovascular infra-renal 
abdominal aortic aneurysm repair and lower extremity bypass72. Half of VSG population was 
submitted to carotid endarterectomy, while only 24% of our population underwent carotid 
surgery72. If we compare the VSG’s results only for open abdominal aortic aneurysm repair, 
their complication rate ranged from 19% to 22%, similar to ours (15%). Additionally, one third 
of our patients underwent urgent/emergent procedures, which are usually associated to 
higher complication rates. 
Underestimation of cardiac risk has serious implications for clinical practice. The decision to 
proceed to surgery or not is based on the risk-benefit ratio. The benefit of elective surgery 
depends on the vascular disease’s complication rate. The annual risk of abdominal aortic 
aneurysm (AAA) rupture depends on its diameter and ranges from 0.5-5% in AAAs between 
4.0 to 4.9 cm, to 30-50% in AAAs with a diameter greater than or equal to 8.0 cm82. In 
patients with PAD and claudication, only 1 to 2 % will progress to critical limb ischemia in 5 
years83. For patients with asymptomatic carotid stenosis, the absolute benefit in stroke 
prevention for revascularization is 1-2% per year84. Previous randomized trials comparing 
carotid endarterectomy with medical therapy were performed before improvements in 
medical therapy85,86. It has been suggested that intensive medical treatment has reduced the 
annual rate of stroke from 2-5% to 1%87,88. Awareness that, patients classified as 
intermediate risk by Lee or VSG, have cardiac event rates around 10% is extremely 
important for the decision of the best treatment choice (surgery vs. medical treatment)26. 
Other comorbidities that could compromise quality of life and may improve with surgery, such 
as chronic pain and poor mobility, also have to be taken into account in this decision. 
Nevertheless, knowledge of the rate of complications is important so that physicians and 
patients together make an informed decision to improve global patient care. For patients 
undergoing urgent or emergent surgery, cancelling or postponing surgery is not an option, 
but estimation of cardiac events rate can also add important clinical information. Indeed, the 
knowledge that cardiac risk in higher than predicted empowers the evaluating physician for 
suggesting measures to reduce risk, such as giving statins, referring the patient to the 
intensive care unit after surgery and recommending surveillance for improving diagnosis and 
treatment of cardiac events. 
Unfortunately, both scores had low to moderate accuracy in our population of unselected 
patients submitted to vascular surgery. This finding may at least in part be explained by the 
fact that both scores do not take into account the intraoperative period. It is well known that 
intraoperative complications including hypotension and bleeding are associated with the 
development of postoperative major cardiac events including death79,89. Nevertheless, VSG 
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score had a better accuracy than Lee score to predict cardiac events, a finding that is in line 
with previous studies71,72. In addition, Lee score could not discriminate well between the 
patients classified in class II and III risk strata. As Lee score had been part of the routine 
clinical preoperative evaluation to guide management at the participating institutions25,26, 
classifying a patient as Lee class ≥ III may have led to changes in perioperative clinical care 
that could have an impact on outcome.  
We have shown that the presence of anaemia is a strong predictor for cardiac events. 
Several previous studies have demonstrated that preoperative anaemia is a predictor of 
short- and long-term mortality after non-cardiac surgery, including vascular surgery90–96. 
However, the evidence for preoperative anemia as a predictor of cardiac events after all 
types of vascular surgery is still limited. In a retrospective study including 360 patients 
undergoing peripheral arterial reconstructive surgery, Oshin et al reported that preoperative 
hemoglobin levels were related not only to mortality but also to cardiac events after surgery97. 
In a large retrospective study evaluating 31,857 elderly patients (> 65 years old) of the 
National Surgical Quality Improvement Program (NSQIP) database undergoing elective 
mostly open vascular procedures, Gupta et al have demonstrated that low preoperative 
hematocrit values were related to mortality and to perioperative MI or cardiac arrest within 30 
days96. In our prospective study, not only did we confirm that preoperative anaemia (as 
defined by WHO criteria) is an independent predictor of cardiac events in patients 
undergoing open or endovascular vascular procedures, but also provide a way to use this 
information in clinical practice. Although VSG score alone had better accuracy than Lee 
score alone in our population, it was equivalent of Lee score plus anaemia. The Lee score is 
simpler to calculate than VSG score and it is the score recommended by most guidelines25,26. 
As haemoglobin is routinely measured prior to surgery, incorporation of this biomarker as a 
power-up in the Lee score is a simple and no cost way of improving cardiac risk prediction.  
Limitations 
Our study has some limitations. First, our patients came from two tertiary centers, where 
patients usually are referred to when they have a more severe vascular disease or important 
cardiac or non-cardiac comorbidities. In the University of São Paulo, we included patients for 
whom cardiac consultation was requested and, although it is common practice at our 
institution for vascular surgeons to request cardiac evaluation for all patients, we may have 
missed patients in the lower risk strata. Second, we did not evaluate the NSQIP39, MICA 
(myocardial infarction/cardiac arrest)38 and Vascular Quality Initiative (VQI)76 risk scores that 
are more complex and accurate than Lee and VSG scores. These scores have to be done 
online or using mobile applications, and only evaluate risk of MI and cardiac death, both 
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factors limiting practical clinical use38,39,76. Currently, with improvement of surgical and 
anaesthetic techniques, patients undergoing non-cardiac surgery are increasingly older and 
have more comorbidities, therefore it is also important to estimate the risk of other common 
cardiac complications besides MI and cardiac arrest, such as AHF and arrhythmias.  
All risk prediction scores have advantages and limitations. They also were tested in different 
populations, different surgical procedures and predict different outcomes. Nevertheless, their 
use is recommended by most guidelines25,26,70. It is up to the attending physician to be aware 
of their individual strengths and limitations and choose the most appropriate one, depending 
on clinical context. Using more than one risk score with different endpoints (VSG score plus 
NSQIP, for example), could be a good option to improve risk prediction and patient care. 
However, it is extremely important to be aware that the incidence of cardiac events is 
probably higher than predicted in order to make appropriate risk-benefit assessments 
regarding surgery. 
Conclusion 
The Lee and VSG scores have low accuracy and underestimate the risk of major 
perioperative cardiac events in unselected patients undergoing vascular surgery, which can 
at least partly be increased for Lee by the addition of preoperative anemia. Underestimation 
of major cardiac complications may lead to incorrect risk-benefit assessments by physicians 
and patients regarding the planned operation. 
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Tables 
Table I Baseline characteristics and outcome divided by hospital 
 
All Patients 
Sao Paulo 
cohort Basel cohort p value 
 
n = 954 n = 743 n = 211 
 
Male gender, n(%) 687 (72) 540 (73) 147 (70) 0.39 
Age (years), median (IQR) 70 (63-76) 68 (62-75) 74 (68-79) <0.001 
Diabetes, n (%) 324 (34) 261 (35) 63 (30) 0.15 
Insulin, n (%) 111 (12) 82 (11) 29 (14) 0.28 
Hypertension, n(%) 795 (83) 627 (84) 168 (80) 0.10 
Active/former smoker, n (%) 725 (76) 564 (76) 161 (76) 0.90 
CAD, n (%) 377 (40) 286 (39) 91 (43) 0.22 
CABG/PCI, n (%) 175 (18) 138 (19) 37 (18) 0.73 
PAD 954 (100) 743 (100) 211 (100) - 
CHF, n (%) 154 (16) 128 (17) 26 (12) 0.09 
NYHA FC ≥ II* 54 (6) 54 (7) NA  
Hx Stroke/TIA, n (%) 232 (24) 195 (26) 37 (18) <0.001 
COPD, n (%) 90 (9) 51 (7) 39 (19) <0.001 
Creatinine† (mg/dL), median (IQR) 1.1 (0.8-1.4) 1.1 (0.9-1.4) 1 (0.8-1.4) 0.008 
CRF in dialysis, n (%) 32 (3.4) 25 (3) 7 (3) 0.97 
Anaemia‡, n (%) 393 (41) 275 (37) 118 (56) <0.001 
Haemoglobin‡ (g/dL), median 
(IQR) 13 (12-14) 13.2 (11.9-14.3) 12.4 (10.3-14) <0.001 
Preoperative medications 
 
   
ASA‡, n (%) 774 (81) 637 (86) 137 (65) <0.001 
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*n= 743; †n=952;  ‡n=953; CAD = coronary artery disease; CABG = coronary artery bypass 
graft surgery; PCI = percutaneous coronary intervention; PAD = Peripheral artery disease 
CHF = chronic heart failure; NYHA FC = New York Heart association functional class Hx = 
previous history; TIA = Transient ischemic attack COPD = chronic obstructive pulmonary 
disease; CRF = chronic renal failure; ASA = aspirin; ACEI = angiotensin-converting enzyme 
inhibitors; ARB = angiotensin receptor blockers; IQR= interquartile range; TT = 
Transthoracic; NA = not available. 
  
Clopidogrel, n (%) 78 (8) 47 (6.3) 31 (15) <0.001 
Statins n (%) 845 (89) 713 (96) 132 (63) <0.001 
Betablockers, n (%) 516 (54) 409 (55) 107 (51) 0.27 
ACEI or ARB, n (%) 556 (58) 425 (57) 131 (62) 0.20 
Preoperative cardiac 
assessment     
Myocardial perfusion imaging, n 
(%) 375 (39) 355 (48) 20 (10) <0.001 
    Normal perfusion, n (%) 201 (21) 201 (27) 0 
<0.001 
    Fixed perfusion defects, n (%) 104 (11) 100 (14) 4 (2) 
    Reversible perfusion defects, n 
(%) 70 (7) 54 (7) 16 (8) 
Coronary angiography, n (%) 67 (9) 39 (5) 28 (13) <0.001 
TT echocardiography, n (%) 392 (41) 392(53) NA NA 
    Wall motion Abnormalities, n 
(%) 96 (10) 96 (13) NA NA 
Primary endpoint 120 (12.6) 102 (13.7) 18 (8.5) 0.045 
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Table II Clinical characteristics of all patients with and without cardiac events 
 
All Patients 
No cardiac 
events 
Cardiac 
events p-value 
 
n = 954 n = 834 n = 120 
 
Male gender, n (%) 687 (72) 604 (72)  83 (69) .46 
Age (years), median (IQR) 70 (63-76) 69 (63-75) 71 (63-78) .04 
Diabetes, n (%) 324 (34) 277 (33) 47 (39) .20 
Insulin, n (%) 111 (12) 93 (11) 18 (15) .35 
Hypertension, n (%) 795 (83) 687 (82) 108 (90) .04 
Active/former smoker, n (%) 725 (76) 626 (75) 99 (82.5) .07 
CAD, n (%) 377 (40) 313 (38) 64 (53) .001 
CABG/PCI, n (%) 175 (18) 140 (17) 35 (29) .001 
PAD 954 (100) - -  
CHF, n (%) 154 (16) 121 (15) 33 (28) < .001 
NYHA FC ≥ IIa 54 (8) 34 (5) 20 (20) .02 
Hx Stroke/TIA, n (%) 232 (24) 204 (25) 28 (23) .79 
COPD, n (%) 90 (9) 79 (10) 11 (9) .92 
Creatinineb (mg/dL), median (IQR) 1.1 (0.8-1.4) 1.1 (0.8-1.4) 1.2 (1.0-1.5) .004 
CRF in dialysis, n (%) 32 (3.4) 29 (4) 3 (3) .79 
Anaemiac, n (%) 393 (41) 323 (39) 70 (58) < .001 
Haemoglobinc (g/dL), median (IQR) 13 (12-14) 13 (12-14) 12 (11-14) < .001 
Preoperative medications 
 
  
 
ASAc, n (%) 774 (81) 669 (80) 105 (88) .06 
Clopidogrel, n (%) 78 (8) 72 (9) 6 (5) .17 
Statins n (%) 845 (89) 734 (88) 111 (93) .15 
Betablockers, n (%) 516 (54) 441 (53) 75 (63) .05 
ACEI or ARB, n (%) 556 (58) 481 (58) 75 (63) .32 
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an= 743; bn=952;  cn=953; CAD = coronary artery disease; CABG = coronary artery bypass 
graft surgery; PCI = percutaneous coronary intervention; PAD = Peripheral artery disease 
CHF = chronic heart failure; NYHA FC = New York Heart association functional class Hx = 
previous history; TIA = Transient ischemic attack COPD = chronic obstructive pulmonary 
disease; CRF = chronic renal failure; ASA = aspirin; ACEI = angiotensin-converting enzyme 
inhibitors; ARB = angiotensin receptor blockers; IQR = interquartile range; TT = 
Transthoracic 
  
Preoperative cardiac assessment     
Myocardial perfusion imaging, n (%) 375 (39) 327(39) 48 (40) .89 
    Normal perfusion, n (%) 201 (21) 176 (21) 25 (21) 
.50     Fixed perfusion defects, n (%) 104 (11) 87 (10) 17 (14) 
    Reversible perfusion defects, n (%) 70 (7) 64 (8) 6 (3) 
Coronary angiography, n (%) 67 (9) 59 (9) 8 (8) .72 
TT echocardiography, n (%) 392 (41) 320 (38) 72 (60) NA 
       Wall motion Abnormalities, n (%) 96 (10) 70 (8) 26 (22)  
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Table III Observed primary endpoint and perioperative MI according to type of surgery 
Type of Surgery 
 
All Patients 
n (%) 
Cardiac events 
n (%) 
Perioperative MI 
n (%) 
Open aortic aneurysm repair 107 (11.2) 16 (15.0) 10 (9.3) 
Endovascular aortic aneurysm 
repair 
200 (21.0) 32 (16.0) 
11 (5.5) 
Lower extremity bypass  219 (23.0) 33 (15.1) 23 (10.5) 
Lower extremity angioplasty 109 (11.4) 14 (12.8) 5 (4.6) 
Carotid endarterectomy 151 (15.8) 15 (9.9) 12 (7.9) 
Carotid stenting 82 (8.6) 3 (3.7) 2 (2.4) 
Amputations 37 (3.9) 5 (13.5) 2 (5.4) 
Others 49 (5.1) 2 (4.1) 1 (2.0) 
MI = myocardial infarction 
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Table IV Observed primary endpoint according to risk strata for each cardiac risk score and 
predicted Risk 
Cardiac Risk 
Scores 
All 
Patients  
n (%) 
Observed  
Cardiac events 
n (%, 95%-CI) 
Predicted 
Risk 
(%) 
Lee Score 
  
 
I 139 (14.6) 11 (8, 4-12) (0.4) 
II 337 (35.3) 39 (12, 8-15) (0.9) 
III 285 (29.9) 33 (12, 8-15) (6.6) 
IV 193 (20.2) 37 (19, 14-25) (11.0) 
VSG 
  
 
0-3 237 (24.8) 11 (5, 2-7)  (2.6) 
4 181(19.0) 15 (8, 4-12)  (3.5) 
5 166 (17.4) 31 (18, 13-25)  (6.0) 
6 124 (13.0) 21 (16, 10-23)  (6.6) 
7 98 (10.3) 15 (15, 8-22)  (8.9) 
>8 148 (15.5) 27 (18, 12-24)  (14.3) 
Lee RCRI = Revised Cardiac Risk Index by Lee; VSG = Vascular Study Group of New 
England Cardiac Risk Index 
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Table V Logistic regression models for prediction of primary outcome including Lee score (A) 
and VSG score (B) 
A) Lee score OR 95%CI p-value 
Age 
Female sex 
Hypertension 
Urgency/emergency 
Smoking 
COPD 
ASA  
statins 
betablockers 
ACEI or ARB 
Lee Score 
Anemia 
1.2 
1.4 
1.5 
1.4 
1.8 
0.8 
1.6 
1.3 
1.2 
1.1 
1.3 
2.0 
1.0 - 1.4 
0.9 - 2.2 
0.7 - 2.9 
0.9 -  2.1 
1.1 - 3.1 
0.4 - 1.7 
0.9 - 3.0 
0.6 - 2.9 
0.8 - 1.9 
0.7 - 1.6 
1.0 - 1.5  
1.3 - 3.0 
0.066 
0.137 
0.283 
0.158 
0.026 
0.610 
0.102 
0.450 
0.303 
0.756 
0.041 
0.001 
B) VSG score OR 95%CI p-value 
Female sex 
Hypertension 
Urgency/emergency 
Supra-inguinal 
surgery 
Stroke/TIA 
ASA 
statins 
ACEI or ARB  
VSG score 
1.3 
1.5 
1.3 
1.1 
0.9 
1.7 
1.5 
1.1 
1.2 
1.9 
0.9 - 2.1 
0.8 - 3.0 
0.8 - 2.1 
0.7 - 1.8 
0.5 - 1.4 
0.9 - 3.0 
0.7 - 3.2 
0.7 - 1.6 
1.1 - 1.4 
1.3 - 2.9 
0.195 
0.213 
0.236 
0.616 
0.607 
0.088 
0.299 
0.770 
< 0.001 
0.002 
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Anemia 
OR = odds ratio; COPD = chronic obstructive pulmonary disease; TIA = Transient ischemic 
attack; ASA = aspirin; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin 
receptor blockers 
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Figures 
Figure I Revised Cardiac Risk Index by Lee35 
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Figure II Vascular Study Group of New England Cardiac Risk Index (VSG)72 
 
COPD = chronic obstructive pulmonary disease; CABG = coronary artery bypass graft 
surgery; PCI = coronary percutaneous intervention; pt = point 
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Figure III Combined endpoint according to risk strata for the Lee score (left) and the VSG 
(right), predicted event rate (green) vs observed event rate (red) 
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Figure IV Receiver operating characteristics curves of Lee (red) vs VSG (green) risk scores 
with 95% confidence intervals for sensitivity 
 
 
74 
 
Figure V Receiver operating characteristics curves of Lee score (red) vs Lee score plus anaemia (blue, panel left) and VSG (green) score vs. VSG 
score plus anaemia (blue, panel right) 
 
  
75 
 
Supplement 
Supplement Figure I Patient Flowchart 
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III Comparison of high-sensitivity cardiac troponin I and T for the 
prediction of cardiac complications after non-cardiac surgery 
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Abstract 
Aims: Predicting cardiac complications after non-cardiac surgery is challenging. We aimed 
to compare the accuracy of preoperative high-sensitivity cardiac troponin (hs-cTn) I and T 
concentration for the prediction of major cardiac complications after non-cardiac surgery. 
Methods: We measured hs-cTnI and hs-cTnT preoperatively in a blinded fashion in 1022 
consecutive patients undergoing non-cardiac surgery. The primary endpoint was a composite 
of major cardiac complications including cardiac death, cardiac arrest, myocardial infarction, 
clinically relevant arrhythmias, and acute heart failure within 30 days. We hypothesized that 
the type of surgery may impact on the predictive accuracy of hs-cTnI/T and stratified all 
analyses according to the type of surgery. 
Results: Major cardiac complications occurred in 108 (11%) patients, 58/243 (24%) patients 
undergoing vascular surgery and 50/779 (6%, p<0.001) patients undergoing non-vascular 
surgery. Among patients undergoing vascular surgery, preoperative hs-cTnI, but not hs-
cTnT, was an independent predictor of major cardiac complications (adjusted odds ratio 
(aOR) 1.5, 95% confidence interval (95%CI) 1.0-2.1). The area under the receiver-operating 
characteristics curve (AUC) was 0.67 (95%CI, 0.59-0.75) for hs-cTnI versus 0.59 (95%CI 
0.51-0.67, p=0.012) for hs-cTnT. In contrast, among patients undergoing non-vascular 
surgery both preoperative hs-cTnI and hs-cTnT were independent predictors of the primary 
endpoint (aOR 1.6, 95%CI 1.3-2.0, and aOR 3.0, 95%CI 2.0-4.6, respectively) and showed 
higher predictive accuracy (AUC 0.77, 95%CI, 0.71-0.83, and 0.79, 95%CI 0.73-0.85, 
p=0.437). 
Conclusions: Preoperative hs-cTnI and hs-cTnT predict major cardiac events after non-
vascular surgery, while only hs-cTnI maintained prognostic accuracy also in patients 
undergoing vascular surgery. 
Keywords: troponin; preoperative care; cardiac complications; non-cardiac surgery 
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Introduction 
More than 300 million surgeries are performed annually worldwide2. Despite advances in 
surgery and anaesthesia, 30-day mortality after non-cardiac surgery remains substantial98,99. 
Cardiac complications, including perioperative myocardial infarction (MI), are important 
contributors to 30-day mortality12,100. Because cardiac complications, particularly MI, maybe 
silent and ECGs at one point in time can miss important changes, accurate detection 
mandates active surveillance. Predicting cardiac complications after non-cardiac surgery is 
difficult and inaccurate, as both patient and surgery related factors seem to matter. A recent 
multicentre study suggested that multivariate risk scores currently recommended have poor 
prognostic accuracy, particularly in patients undergoing vascular surgery101. Thus, it remains 
challenging to quantify the risk-benefit ratio of planned operations or to test interventions that 
might be preventative or therapeutic.  
The use of cardiac biomarkers could improve the prediction of cardiac complications after 
non-cardiac surgery. Pilot studies by several groups including ours have suggested that 
preoperative high-sensitivity cardiac troponin T (hs-cTnT) blood concentrations seem to 
improve risk prediction in non-cardiac surgery when added to the Revised Cardiac Risk 
Index (RCRI)31,41. The role of high-sensitivity cardiac troponin I (hs-cTnI) in predicting cardiac 
complications after non-cardiac surgery remains largely unknown. It is also unknown, 
whether one cardiac troponin signal is more accurate than the other, and/or whether the type 
of surgery may impact on the relative accuracy of hs-cTnT versus hs-cTnI. 
The aim of our study was to compare the accuracy of preoperative hs-cTnI and hs-cTnT for 
the prediction of major cardiac complications after non-cardiac surgery. 
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Methods 
Patients 
Between May 2014 and March 2016, patients undergoing non-cardiac surgery (vascular and 
non-vascular surgery) were studied in two University hospitals, including consecutive adult 
patients scheduled for planned or urgent, open or endovascular arterial vascular surgery at 
the Clinics Hospital, University of Sao Paulo Medical School, Brazil, and consecutive patients 
undergoing major non-cardiac surgery (vascular and non-vascular) from April to December 
2015, at the University Hospital Basel, Switzerland. Inclusion criteria were age above 65 
years OR and history of coronary artery disease, peripheral artery disease, or 
cerebrovascular disease.  
For this analysis, we excluded patients with acute MI, stroke, or pulmonary embolism in the 
week preceding the operation because these events substantially influence both the risk of 
cardiac complications and blood concentration of cTnI and cTnT. For the main analysis, 
patients with missing hs-cTnI or hs-cTnT preoperative values were excluded. 
Local ethics committees approved the protocol (EKNZ 2015/301 in Basel and CAPPESQ 
610608 in Sao Paulo) and written informed consent was provided. 
Perioperative assessment  
Before surgery, clinical evaluation and an electrocardiogram (ECG) were performed. 
Patients’ cardiac risk was classified based on the Revised Cardiac Risk Index (RCRI)35. 
Additional cardiac tests, such as echocardiogram or myocardial perfusion imaging tests, 
were performed at the discretion of the attending physician. Definitions of previous coronary 
artery disease (CAD), chronic heart failure (CHF) and anaemia are reported in the 
supplementary material online73,102.  
As recommended by our Institution and international guidelines, we used active surveillance 
in the detection of major cardiac complications after non-cardiac surgery17,103. Hs-cTnT blood 
concentrations were measured preoperatively, on the first and second postoperative day, 
and whenever symptoms suggestive of MI occurred. Routine 12-lead ECG was performed 
daily until the third postoperative day in Sao Paulo, in case of a relevant absolute increase in 
hs-cTnT (absolute change of 14ng/L or more) in Basel, and in both cohorts whenever 
symptoms suggestive of MI or arrhythmias occurred. Patients were followed-up for 30 days 
after surgery. 
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Troponin measurements  
Blood samples for the determination of hs-cTnI (ARCHITECT High Sensitive STAT Troponin 
I assay, Abbott Laboratories) and hs-cTnT (Elecsys, Roche diagnostics, Mannheim, 
Germany) were collected once before surgery (within 30 days) and on the first and second 
postoperative days.  
The hs-cTnI assay has a limit of blank (LoB) between 0.7-1.3ng/L, limit of detection (LoD) 
between 1.1-1.9ng/L and a 99th percentile upper reference limit (URL) of 13ng/L according to 
recent studies104–109. As other population studies had proposed a 99th percentile of 26ng/L109, 
this cut-off was used for a secondary analysis reported in the supplementary material online. 
Sex-specific cut-offs are also available in the supplementary material online.  
The hs-cTnT assay has a LoB of 3ng/L, a LoD of 5ng/L and a 99th percentile URL of 14ng/L.  
In the cohort of vascular surgery patients, sensitive cardiac Troponin I (s-cTnI, Siemens 
Ultra, Advia Centaur immunoassay system) was also obtained. The s-cTnI assay has a LoD 
of 6ng/L and a 99th percentile of 40ng/L.  
Clinical endpoints 
The primary endpoint was a composite of major cardiac complications including cardiac 
death, cardiac arrest, perioperative MI, clinically relevant arrhythmias, and acute heart failure 
(AHF) within 30 days. Two independent physicians adjudicated all MI cases according to the 
criteria defined in the Third Universal Definition of Myocardial Infarction for spontaneous MI17. 
Accordingly, MI was diagnosed in patients with acute cardiomyocyte necrosis exceeding the 
99th percentile of the hs-cTn assay, used in clinical practice in both centres (hs-cTnT), 
accompanied by either ischemic symptoms, new ECG changes or imaging evidence of loss 
of viable myocardium. Arrhythmia (atrial fibrillation/flutter, supraventricular tachycardia, 
ventricular tachycardia) was considered clinically significant if requiring drug therapy or 
electrical cardioversion. The attending cardiologist diagnosed AHF using clinical symptoms, 
physical examination, chest x-ray, BNP or NT-proBNP blood concentrations, and 
echocardiography102,110,111. Deaths were considered cardiovascular in the absence of a clear 
non-cardiac cause, as suggested in recent recommendations62. The secondary endpoint was 
all-cause mortality within 30 days of surgery. Patients were followed-up in outpatient clinic 
consultations, by phone, or by contacting their primary care physician. Additionally, study 
personnel requested reports from the general practitioners, treating facilities or death 
registries.  
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Statistical analysis 
Categorical variables are shown as numbers and percentages and were compared by 
Fisher’s exact test. Continuous variables are presented as medians and interquartile range 
(IQR) and were compared by Mann-Whitney-U test.  
Based on our recent finding of very high cardiac event rate in patients undergoing vascular 
surgery and very poor accuracy of existing risk prediction tools in these patients101, we 
prospectively decided to stratify the analysis according to the type of surgery (vascular 
versus non-vascular). We calculated the interaction p-value for the prognostic value of hs-
cTn with the type of surgery for the combined endpoint using a binary logistic regression 
model.  
We did multivariable binary logistic regression analysis for each available troponin assay 
adjusted for a selection of predefined covariables (age, sex, CAD, CHF, stroke, diabetes 
mellitus, hypertension, dialysis, and anaemia). Covariables were chosen by best predictive 
value for the primary endpoint and according to the number of events (one covariable per 10 
events).  
Receiver operating characteristic curves (ROC) were constructed to assess accuracy of the 
troponin assays for prediction of primary endpoint, and compared by de Long method. Then, 
we combined each troponin assay with the RCRI (by calculating mean predicted values 
using binary logistic regression), and evaluated whether there was improvement of risk 
prediction. Troponin values were log-transformed for this analysis and for the models. We 
also performed correlation analysis of preoperative hs-cTnI, hs-cTnT, haemoglobin, and 
estimated glomerular filtration rate (eGFR, calculated by CKD-EPI formula) values by 
Spearman’s test.  
ROC analyses were repeated for the secondary endpoint all-cause death. 
To further test the different behaviour of hs-cTnT in vascular and non-vascular patients, we 
performed a post-hoc analysis comparing AUC of hs-cTnT in vascular versus non-vascular 
patients, including all patients for whom preoperative hs-cTnT was available, irrespective of 
missing hs-cTnI values. 
P-values of <0.05 were considered to indicate statistical significance. Analyses were 
performed using SPSS 22 (IBM Co, NY, USA) and R software (version 3.1.3, “pROC”)81.  
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Results 
Baseline characteristics 
Flowchart of patient’s inclusion is shown in Supplement Figure A. Baseline characteristics 
of the 1022 patients included in the main analysis are shown in Table A. Detailed surgical 
characteristics are shown in Supplement Table A. In brief, 243 patients underwent vascular 
surgeries (mainly open or endovascular aortic aneurysm repair, lower extremity bypass, or 
carotid surgery) and 779 patients underwent non-vascular surgeries (mainly 
orthopaedic/trauma, urologic, spinal, or visceral surgery). 807 (79%) surgeries were planned, 
and the remaining 215 (21%) were urgent or emergent.  
Preoperative levels of troponin 
Preoperatively, hs-cTnI levels were detectable in 100%, hs-cTnT levels in 98%, and s-cTnI in 
60% of patients. Absolute levels are shown in Supplement Table B. The prevalence of 
baseline cTn levels above the 99th percentile was lower for hs-cTnI than for hs-cTnT assay 
(Figure A).  
Overall, correlation between hs-cTnI and hs-cTnT values was good (r>0.6) and comparable 
in vascular and non-vascular subgroups. Hs-cTn levels were also correlated with eGFR and 
haemoglobin (Supplement Table C). 
Clinical outcomes 
The primary combined endpoint of major cardiac complications occurred in 108/1022 (10.6%, 
95%CI 8.8-12.7) patients, with events occurring four-times more often after vascular surgery 
with an incidence of 58/243 (24%, 95%CI 19.0-29.9) versus 50/779 (6.4%, 95%CI 4.9-8.4, 
p<0.001) after non-vascular surgery (Table B). 
Prediction of the primary endpoint: major cardiac complications 
Patients with major cardiac complications had higher baseline median cTn blood 
concentrations with all assays than patients without complications. In vascular surgery 
patients, median baseline hs-cTnI was 8ng/L (IQR 4-15) vs. 5ng/L (IQR 3-8; p<0.001), 
median hs-cTnT was 14ng/L (IQR 9-19) vs. 10ng/L (IQR 6-17; p=0.039) and median s-cTnI 
was 11ng/L (IQR 6-23) vs. 7ng/L (IQR 6-14; p=0.002), respectively for patients with vs 
without cardiac complications.  
In non-vascular surgery patients, median baseline hs-cTnI was 12ng/L (IQR 7-29) vs. 4ng/L 
(IQR 2-8; p<0.001) and median hs-cTnT was 40ng/L (IQR 15-64) vs. 13ng/L (IQR 7-22; 
p<0.001), respectively.  
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In vascular surgery patients, the prognostic accuracy for major cardiac complications of hs-
cTnI was higher than hs-cTnT, with an AUC of 0.67 (95%CI 0.59-0.75) versus 0.59 (95%CI 
0.51-0.67, p=0.012, Figure B). 
In non-vascular surgery patients, the overall AUC was higher than in vascular surgery and 
hs-cTnI and hs-cTnT showed comparable AUCs of 0.77 (95%CI 0.71-0.83) versus 0.79 
(95%CI 0.73-0.85, p=0.437, Figure B).  
We found a significant interaction p-value for hs-cTnI (p=0.011) as well as hs-cTnT (p<0.001) 
with the type of surgery in regard to predictive value for major cardiac complications. 
In multivariable analysis, in vascular surgery patients, only baseline hs-cTnI (but not hs-
cTnT) remained an independent predictor of the primary endpoint (Table C), while in non-
vascular surgery patients, both baseline hs-cTnI and hs-cTnT were independent predictors of 
major cardiac complications (Table D). 
In vascular patients, the RCRI showed a comparable predictive accuracy as quantified by 
AUC compared to hs-cTnI, hs-cTnT, and s-cTnI. Combination of RCRI and cTn yielded non-
significantly improved AUCs (Figure C). In contrast, in non-vascular patients, the RCRI 
showed a significantly lower AUC than hs-cTnI (p=0.04) and hs-cTnT (p=0.01) and adding 
RCRI to hs-cTn measurements did not improve the AUC (Figure C). 
In the ancillary analysis of all patients with hs-cTnT values available (n=2495, Supplement 
Figure A), we found an AUC for hs-cTnT of 0.55 (95%CI 0.48-0.62) in vascular surgery 
patients versus 0.75 (95%CI 0.70 – 0.79; p <0.001) in non-vascular surgery patients. 
Prediction of the secondary endpoint: all -cause mortality 
All-cause mortality occurred in 33/1022 (2.9%) of all patients within 30-days, significantly 
more often in patients undergoing vascular surgery (8% vs 2%, p<0.001). Preoperative hs-
cTnI, hs-cTnT, and s-cTnI concentrations provided comparable accuracy in the prediction of 
all-cause mortality in vascular surgery patients, but in non-vascular surgery hs-cTnT showed 
a markedly higher AUC than hs-cTnI, despite being non-significant with p=0.05 (Figure D).  
Postoperatively, considering peak values in the first 3 days after surgery, the number of 
patients with values above 99th percentile increased for all assays in both cohorts (Figure A). 
Using the peak postoperative troponin values, all assays could predict 30-day mortality with 
good accuracy in both cohorts (Supplement Figure B). 
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Discussion 
To the best of our knowledge this is the first study directly comparing preoperative hs-cTnI 
and hs-cTnT measurements in the prediction of major cardiac complications after non-
cardiac surgery. We report four major findings. First, although using a biological equivalent 
99th percentile cut-off concentration for hs-cTnI and T consistently documented in two recent 
large studies104,108, preoperative hs-cTnT elevations were more than twice as common as 
preoperative hs-cTnI elevations. This finding emerged irrespective of the type of surgery. 
Second, the absolute increase in hs-cTn blood concentration was higher in patients 
undergoing vascular surgery as compared to non-vascular surgery, and this finding emerged 
for both hs-cTnI and hs-cTnT. Third, among patients undergoing vascular surgery, 
preoperative hs-cTnI, but not hs-cTnT, was an independent predictor of major cardiac 
complications. Fourth, among patients undergoing non-vascular surgery, both preoperative 
hs-cTnI and hs-cTnT blood concentrations were independent predictors of major cardiac 
complications after non-cardiac surgery.  
This study corroborates and extends previous studies evaluating preoperative hs-cTnT 
measurements, and is the first to comprehensively evaluate hs-cTnI. Several previous 
studies addressed the role of hs-cTnT in non-cardiac surgery31,41. We have confirmed the 
findings of previous authors that 21-41% of patients have hs-cTnT levels above 99th 
percentile before surgery30,40,65, and that this number can increase up to 45-60% after 
surgery. We have shown for the first time that high preoperative levels of hs-cTnI are less 
frequent than those of hs-cTnT. This finding is in line with a recent study evaluating 
prevalence of hs-cTn elevations in patients admitted to the hospital without acute coronary 
syndromes (ACS), in which the authors reported that elevations of hs-cTnT above the 99th 
percentile were present in more than one third of non-ACS patients whereas hs-cTnI 
elevations were present in only one tenth112. In another study evaluating only hs-cTnT in 
patients admitted to the emergency department due to non-ACS reasons, the authors found 
that half of the patients had hs-cTnT blood concentrations above 99th percentile113. 
In patients submitted to non-cardiac surgery, it has been shown that preoperative hs-cTnT is 
a predictor of post-operative cardiac complications31,41, and our study corroborates with this 
finding. In the subgroup of patients undergoing vascular surgery, although it seems clear that 
an elevated hs-cTnT value before or after surgery is a predictor for short- and long-term all-
cause mortality, there is still conflicting evidence regarding the role of preoperative hs-cTnT 
elevations in predicting cardiac complications, including perioperative MI40,46,65. We have 
demonstrated that preoperative hs-cTnT values have different predictive value in patients 
undergoing vascular and non-vascular surgery. In vascular patients, although preoperative 
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hs-cTnT is not a good predictor of major cardiac complications, it is good for predicting all-
cause mortality. In contrast, in non-vascular surgery patients, both preoperative hs-cTnI and 
T are also good predictors for cardiac complications. We have confirmed these findings in an 
additional analysis of all patients for whom only hs-cTnT was available. One possible 
explanation is that the mechanism of perioperative MI may be different in vascular and non-
vascular surgery patients. Vascular patients have more severe diffuse atherosclerotic 
disease and the procedure itself, including manipulation of the arterial bed, could trigger 
processes leading to plaque rupture and type 1 MI13. Therefore, preoperative baseline hs-
cTnT values (maybe a surrogate for patients with more severe systemic disease) are less 
useful predictors for cardiac complications after vascular surgery, and only hs-cTnI reached 
statistical significance in our cohort. On the other hand, patients submitted to non-vascular 
surgeries were older and had less previous coronary events but more severe systemic 
disease, which could lead to a type 2 MI, AHF, or arrhythmias65,114. Therefore, in non-cardiac 
surgery patients, blood concentration of hs-cTnT can predict cardiac events as well as hs-
cTnI.  
These findings highlight the differences between the information provided by hs-cTnI and hs-
cTnT in the perioperative setting. We explored the correlation between hs-cTnI and hs-cTnT 
in both cohorts and found it to be weaker than in studies enrolling patients presenting with 
suspected MI to the emergency department104,115. Hs-cTnT seemed more strongly correlated 
to renal dysfunction and anaemia than hs-cTnI, confirming initial pilot findings in patients 
hospitalized without acute coronary syndromes112. This may indicate that cTnT levels suffer 
more interference from non-cardiac factors than cTnI, and high levels of hs-cTnT may be 
related to severe systemic, non-coronary conditions. This could in part also explain the 
observation of a numerically higher prognostic performance for all-cause death observed in 
our study. 
There are some possible explanations for potential differences in the information provided by 
cTnI and cTnT. First, cTnT exists in both cardiac and skeletal muscles of the foetus116. In 
patients with inflammatory muscular diseases, silent genes that codify cTnT in skeletal 
muscles can be reactivated leading to elevated hs-cTnT values42. Further findings of 
markedly elevated hs-cTnT levels in patients with peripheral artery disease and limb 
ischemia raise the hypothesis that this might influence the predictive accuracy in vascular 
patients117. However, this has to be investigated in more detail before conclusions can be 
drawn. Cardiac troponin I seems to be exclusively released by myocardial cells, so its 
release may be more specific for heart diseases42. Second, the mechanism responsible for 
release of cTn of the heart may be due to direct cardiomyocyte injury caused by systemic 
conditions, such as sepsis or inflammation55, independent of the presence of CAD. Previous 
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biochemical studies have showed that correlation between different hs-cTnI assays is better 
than between hs-cTnI and T, and that these differences cannot be explained by analytical 
imprecision alone, therefore, implying a biological difference in the release mechanism of 
cTnI and T118. 
Additionally, we have confirmed that preoperative and peak postoperative hs-cTnT levels 
have good accuracy for prediction of 30-day all-cause mortality30,31,40,41,46,65. Postoperative 
blood concentrations of hs-cTnI and hs-cTnT were even more accurate predictors of 30-day 
mortality as these also potentially reflect the extent of cardiomyocyte injury caused by 
intraoperative complications including bleeding, hypotension, and cardiac arrhythmias. 
Patients submitted to vascular surgery had a higher increase in cTn blood concentrations in 
both assays, probably due to these intraoperative variables.  
Overall, measurement of hs-cTn preoperatively improves the prediction of cardiac 
complications after non-vascular surgery, and should be implemented in clinical practice, 
since it is better than currently used risk scores, such as the RCRI. In patients undergoing 
vascular surgery, hs-cTnI may be preferable than hs-cTnT. These biomarkers may be used 
not only to assess more accurately the risk-benefit of surgery, but also to recommend 
measures to reduce risk, such as giving statins, referring the patient to the intensive care unit 
after surgery and performing surveillance for improving diagnosis and treatment of cardiac 
events. 
Several limitations should be considered when interpreting our findings. First, the sample 
size of patients undergoing vascular surgery was only moderate. However, this seemed to 
have been compensated by the high event rate in these patients. Second, in the non-
vascular surgery cohort, only high-risk patients defined as age ≥65 years or pre-existing 
atherosclerotic disease including CAD, cerebrovascular disease, or PAD were included. We 
can therefore not comment on the risk prediction in low-risk patients undergoing non-
vascular surgery. Third, we measured both clinically available hs-cTn assays, one measuring 
hs-cTnI and one measuring hs-cTnT. Further studies are necessary to examine additional 
hs-cTnI and hs-cTnT assays that are in development. Fourth, it is possible that vascular 
patients were more closely monitored in routine clinical care as they are seen as high-risk 
cohort25. Therefore, the difference in event rate between vascular and non-vascular surgery 
may have been slightly overestimated.  
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Conclusion 
In conclusion, preoperative hs-cTnI and hs-cTnT predict major cardiac events after non-
vascular surgery, while only hs-cTnI maintained prognostic accuracy in patients undergoing 
vascular surgery. 
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Tables 
Table A Baseline characteristics, shown for the whole cohort and split according to surgery 
type. Data shown as counts (n) with percentage (%) or median with interquartile range (IQR) 
  
All Patients 
n = 1022 
Vascular 
n = 243 
Non-vascular 
n = 779 
p-value 
Male gender, n (%) 640 (63) 178 (73) 462 (59) <0.001 
Age (years), median (IQR) 72 [68-78] 68 [62-74] 74 [69-79] <0.001 
Diabetes mellitus, n (%) 282 (28) 89 (37) 193 (25) <0.001 
Hypertension, n (%) 718 (70) 204 (84) 514 (66) <0.001 
Coronary artery disease, n 
(%) 
310 (30) 95 (39) 215 (28) 0.001 
CABG/PCI, n (%) 183 (18) 52 (21) 131 (17) 0.104 
Peripheral artery disease, n 
(%) 
349 (34) 243 (100) 106 (13) <0.001 
Chronic heart failure, n (%) 148 (14) 39 (16) 109 (14) 0.465 
Stroke/transient ischemic 
attack, n (%) 
136 (13) 60 (25) 76 (10) <0.001 
COPD, n (%) 126 (12) 11 (5) 115 (15) <0.001 
Renal failure in dialysis, n 
(%) 
14 (1) 8 (3) 6 (1) 0.007 
Anaemia*, n (%) 456 (45) 86 (36) 370 (48) <0.001 
Preoperative medications 
    
Acetylsalacylic acid, n (%) 438 (43) 208 (86) 230 (30) <0.001 
Statins n (%) 552 (54) 221 (91) 331 (42) <0.001 
Betablockers, n (%) 431 (42) 125 (51) 306 (39) 0.001 
ACEI or ARB, n (%) 552 (54) 150 (62) 402 (52) 0.006 
Revised cardiac risk index 
    
I 361 (35) 25 (10) 336 (43) 
<0.001 
II 352 (34) 86 (35) 266 (34) 
III 208 (20) 84 (35) 124 (16) 
IV 101 (10) 48 (20) 53 (7) 
Laboratory assessment 
    
Creatinine (mg/dL), median 
(IQR) 
0.94 [0.76-1.23] 1.14 [0.92-1.36] 0.9 [0.72-1.14] <0.001 
eGFR (ml/min) 73 [54-88] 64 [49-80] 77 [56-88] <0.001 
Haemoglobin* (g/dL), 
median (IQR) 
12.8 [11.2-14] 13.3 [12.1-14.2] 12.6 [10.9-13.9] <0.001 
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*n=1020; CABG = coronary artery bypass graft surgery; PCI = percutaneous coronary 
intervention; COPD = chronic obstructive pulmonary disease; ACEI = angiotensin-converting 
enzyme inhibitors; ARB = angiotensin receptor blockers; eGFR = estimated glomerular 
filtration rate  
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Table B Clinical outcomes within 30 days, shown for full cohort and split for surgery type 
    
All patients 
n = 1022 
Vascular surgery 
n = 243 
Non-vascular 
n = 779 
p-value 
Major cardiac complication 108 (11%) 58 (24%) 50 (6%) <0.001 
 
Cardiovascular death 11 (1%) 4 (2%) 7 (1%) 0.302 
 
Cardiac arrest 8 (1%) 3 (1%) 5 (1%) 0.404 
 
Myocardial infarction 57 (6%) 32 (13%) 25 (3%) <0.001 
 
Acute heart failure 37 (4%) 23 (45%) 14 (2%) <0.001 
 
Arrhythmia 24 (3%) 18 (49%) 6 (1%) <0.001 
All-cause mortality 33 (3%) 19 (8%) 14 (2%) <0.001 
Comparison done with Fisher’s exact test; multiple events possible in one patient 
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Table C Multivariable logistic regression models using different cardiac troponin assays for 
prediction of major cardiac complications in vascular patients; hs-cTn = high-sensitivity 
cardiac troponin; logn = natural logarithm; s-cTn = sensitive cardiac troponin 
Models predicting combined endpoint 
vascular surgery 
Odds ratio (95%CI) p-value 
Model with hs-cTnI 
  
 
Hs-cTnI, per logn increase 1.5 (1.0-2.1) 0.035 
 
Age, per year 1.0 (1.0-1.1) 0.071 
 
Sex - male 1.5 (0.7-3.0) 0.284 
 
Coronary artery disease 1.5 (0.8-2.9) 0.222 
 
Chronic heart failure 1.9 (0.9-4.3) 0.112 
 
Renal failure in dialysis 2.3 (0.5-11.3) 0.301 
Model with hs-cTnT     
 
Hs-cTnT, per logn increase 1.0 (0.6-1.7) 0.970 
 
Age, per year 1.0 (1.0-1.1) 0.024 
 
Sex – male 1.5 (0.7-3.0) 0.286 
 
Coronary artery disease 1.6 (0.8-3.1) 0.156 
 
Chronic heart failure 2.4 (1.1-5.3) 0.031 
 
Renal failure in dialysis 3.4 (0.6-20.4) 0.173 
Model with sensitive cTnI     
 
S-cTnT, per logn increase 1.4 (0.8-2.3) 0.188 
 
Age, per year 1.0 (1.0-1.1) 0.022 
 
Sex – male 1.4 (0.7-3.0) 0.340 
 
Coronary artery disease 1.7 (0.8-3.3) 0.140 
 
Chronic heart failure 1.9 (0.8-4.5) 0.137 
  Renal failure in dialysis 2.6 (0.5-12.8) 0.247 
logn = natural logarithm; 95%CI = 95% confidence interval 
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Table D Multivariable logistic regression models using different cardiac troponin assays for 
prediction of major cardiac complications in non-vascular surgery patients; hs-cTn = high-
sensitivity cardiac troponin; logn = natural logarithm 
Models predicting combined endpoint 
non-vascular surgery 
Odds ratio (95%CI) p-value 
Model with hs-cTnI 
  
 
Hs-cTnI, per logn increase 1.6 (1.3-2.0) <0.001 
 
Age, per year 1.0 (1.0-1.1) 0.094 
 
Stroke/transient ischemic attack 2.3 (1.1-4.8) 0.035 
 
Diabetes mellitus 3.3 (1.8-6.1) <0.001 
 
Anaemia 3.0 (1.4-6.4) 0.004 
Model with hs-cTnT     
 
Hs-cTnT, per logn increase 3.0 (2.0-4.6) <0.001 
 
Age, per year 1.0 (1.0-1.1) 0.182 
 
Stroke/transient ischemic attack 2.5 (1.2-5.5) 0.019 
 
Diabetes mellitus 2.8 (1.5-5.2) 0.002 
  Anaemia 2.0 (0.9-4.4) 0.077 
logn = natural logarithm; 95%CI = 95% confidence interval 
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Figures 
Figure A Prevalence of cardiac troponin (cTn) levels above the 99th percentile before and 
after vascular and non-vascular surgery, shown for high-sensitivity cTn (hs-cTn) I and T as 
well as sensitive-cTnI in for vascular surgery patients 
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Figure B Area under the receiver operating characteristics curves (AUC) of the different troponin assays measured preoperatively for prediction of 
cardiac complications following A) vascular; and B) non-vascular surgery, shown with 95% confidence intervals 
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Figure C Area under the receiver operating characteristics curves (AUC) with 95% confidence intervals (CI) of cardiac troponin (cTn) assays, the 
Revised Cardiac Risk Index (Lee score), and the combinations of cTn and Lee score for prediction of primary endpoint for A) vascular; and B) non-
vascular surgery patients  
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Figure D Area under the receiver operating characteristics curves of the different troponin assays measured preoperatively for prediction of 
postoperative all-cause mortality in A) vascular; and B) non-vascular surgery patients, shown with 95% confidence intervals 
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Supplement 
Perioperative assessment  
Previous coronary artery disease (CAD) was considered in the presence of history of MI, 
chronic typical exercise-induced angina pectoris, previous coronary revascularization 
(coronary artery bypass graft or percutaneous coronary intervention), or evidence of CAD in 
myocardial perfusion imaging (presence of fixed or reversible perfusion defects) or in 
coronary angiography.  
Preoperative chronic heart failure (CHF) was considered if there were: clinical symptoms 
consistent with CHF, left ventricle ejection fraction (LVEF) lower than 50% assessed by 
echocardiography or LVEF lower than 45% assessed by GATED SPECT obtained during 
myocardial perfusion imaging. In cases with diagnostic uncertainty, B-type natriuretic peptide 
(BNP) or NT-proBNP were measured102. Anaemia was diagnosed according to WHO criteria 
as haemoglobin levels below 130g/L in men and 120g/L in women73. 
Troponin measurements  
After blood collection, one aliquot of the blood sample was immediately processed, from 
which hs-cTnT was measured. In Basel, hs-cTnI was also measured from this sample; in 
Sao Paulo hs-cTnI was measured from serum that was frozen at -80°C in a batch. Prior the 
analysis, samples were homogenized by inversion and centrifuged at 3,000g for 10 minutes 
in order to remove particulate matter. 
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Supplement Table A Types of vascular and non-vascular procedures 
Type of surgery 
Frequency, n (%) 
n = 1022 
Vascular surgeries 
 
 Aortic aneurysm 95 (9) 
 Peripheral artery disease 74 (7) 
 Carotid stenosis 65 (6) 
 Other vascular 9 (1) 
Non-vascular surgeries   
 Orthopedic/Trauma 246 (24) 
 Spinal 142 (14) 
 Thoracic 84 (8) 
 Urologic 176 (17) 
 Visceral 106 (10) 
  Other non-vascular 25 (2) 
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Supplement Table B Blood concentration of cardiac troponin (cTn) measured by different 
assays and absolute number of patients above the 99th-percentile cut-off, shown for the 
whole cohort and according to surgery type 
    
All Patients 
n = 1022 
Vascular 
n = 243 
Non-vascular 
n = 779 
p-value 
Preoperative measurements 
    
High-sensitivity cTn I 
   
  
 
Preoperative level, ng/L 5 (3-9.4) 5 (3-10) 4 (3-9) 0.038 
 
Above cut-off (>13ng/L), n (%) 171 (17) 40 (17) 131 (17) 1 
 
Above cut-off (>26ng/L), n (%) 84 (8) 18 (7) 66 (8) 0.689 
 Above sex specific (>34/16ng/L), n 
(%) 
119 (12) 23 (10) 96 (12) 0.253 
High-sensitivity cTn T 
   
  
 
Preoperative level, ng/L 13 (7-22) 11 (7-18) 13 (8-24) 0.002 
 
Above cut-off (>14ng/L), n (%) 450 (44) 87 (36) 363 (47) 0.003 
Sensitive cTn I 
   
  
 
Preoperative level, ng/L - 8 (6-16)* - - 
  Above cut-off (>40ng/L), n (%) - 17 (8)* - - 
Postoperative measurements 
    
High-sensitivity cTn I 
   
  
 
Postoperative peak level, ng/L 7 (4-17.5) 10 (5-26) 6 (4-15) <0.001 
 
Above cut-off (>13ng/L), n (%) 282 (30) 95 (40) 187 (27) <0.001 
 
Above cut-off (>26ng/L), n (%) 164 (17) 58 (24) 106 (15) 0.002 
 Above sex specific (>34/16ng/L), n 
(%) 
213 (23) 75 (31) 138 (20) <0.001 
High-sensitivity cTn T 
   
  
 
Postoperative peak level, ng/L 18 (10-32) 19 (12-35) 17 (10-31) 0.043 
 
Above cut-off (>14ng/L), n (%) 609 (60) 150 (62) 459 (59) 0.453 
Sensitive cTn I 
   
  
 
Postoperative peak level, ng/L - 21 (12-68)* - - 
  Above cut-off (>40ng/L), n (%) - 68 (30)* - - 
IQR=interquartile range; *n=224 
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Supplement Table C Correlation of cardiac troponins I and T with each other and other 
biochemical signals, split for vascular surgery and non-vascular surgery; all correlations 
p<0.001 
  hs-cTnI hs-cTnT eGFR Hemoglobin 
Vascular surgery 
    
hs-cTnI x 0.64 -0.37 -0.16 
hs-cTnT 0.64 x -0.42 -0.26 
Non-vascular surgery         
hs-cTnI x 0.68 -0.32 -0.28 
hs-cTnT 0.68 x -0.39 -0.41 
hs-cTnT = high sensitivity cardiac troponin T; hs-cTnI = high sensitivity cardiac troponin I; 
eGFR = estimated glomerular filtration rate, calculated with the CKD-EPI formula 
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Supplement Figure A Patient selection from the two studies; AMI = acute myocardial 
infarction, hs-cTn = high-sensitivity cardiac troponin 
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Supplement Figure B Area under the receiver operating characteristics curves (AUC) of peak postoperative measurements of the different 
troponin assays for prediction of postoperative all-cause death following A) vascular; and B) non-vascular surgery, shown with 95% confidence 
intervals 
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Discussion and Outlook 
The aim of this PhD study was to contribute to improving perioperative care after non-cardiac 
surgery, by establishing a large prospective cohort study and investigating PMI. In the years 
since the conception of this study, an increasing number of publications have added to our 
understanding of this topic. Nonetheless, with our stringent methodology, large study size 
and international collaboration we were able to gain important and novel insights. To our 
knowledge, ours is to date the largest study using a prospective definition of PMI. 
Novel insights into PMI 
Incidence 
We found that PMI is a common complication of non-cardiac surgery in high-risk patients, 
occurring in one out of seven patients. A wide range of PMI rates has been reported in recent 
literature3,5,12,30,37, very possibly reflecting differences in patient population, surgical 
procedures and, most importantly, definitions of PMI. Different definitions have been 
proposed, but even in the largest cohort, the VISION study, which originally introduced a 
focus on maximum postoperative hs-cTn levels3, more recent publications arising from the 
study have begun to incorporate change to preoperative levels as used in our study and 
others12,65. As this reflects injury time related to surgery instead of also chronic elevations, 
such a definition might be more appropriate than one using only postoperative values. For 
this reason, our data could substantially improve perioperative care by quantifying the 
incidence of PMI according to a clear cut-off level in line with the hs-cTn criterion used for the 
diagnosis of spontaneous AMI17. This could be easily replicated in future studies. 
Outcome 
We found that patients with PMI had a markedly increased 30-day mortality, a six-fold 
increase compared to patients without PMI. This estimate is probably lower than that of an 
unscreened population, as patients in our cohort were often seen by a cardiologist and had 
adaptations to their treatment regimen, something which is not routinely done in settings 
without systematic PMI detection. The excessive mortality associated with PMI persisted up 
to one year and was similar in asymptomatic PMI and PMI fulfilling any additional criteria 
required for spontaneous AMI17, highlighting the relevance of PMI detected only by a hs-cTn 
criterion. These findings corroborate the finding of increased mortality associated with PMI, 
even though the range of estimates, as with incidence, varies according to studied population 
and definition of PMI. The consistency of an increased mortality associated with PMI 
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highlights the importance of PMI as a perioperative cardiac complication, and will hopefully 
spark future research from various research groups.  
Subtypes 
In order to shed light on the pathophysiology of PMI, we prospectively evaluated all cases 
and made a sub-characterisation of PMI cases according to suspected aetiology. The most 
common type of PMI (>80%) is the cardiac subtype, which is associated with an increased 
30-day and continuously rising one-year risk compared to patients without PMI. This might 
reflect a mix of three factors: 1) increased acute mortality risk following the PMI, 2) increased 
long-term event rate resulting from a lack of treatment of myocardial injury, potentially 
leading to arrhythmias or heart failure, and 3) elevated overall risk reflecting the higher 
prevalence of comorbidities in patients experiencing a PMI. In contrast to this stand, PMI 
resulting from an extra-cardiac cause, e.g. severe sepsis, has a different outcome than those 
with a presumed cardiac cause, with a very high short-term mortality and a relatively stable 
mortality after the initial peak of up to one year after surgery. The initial mortality peak might 
reflect the very high mortality of the extra-cardiac disease, such as severe sepsis which 
usually has a mortality rate of between 4–42% despite intensive care, including close 
monitoring in an intensive care unit, optimal medical treatment, and follow-up119,120. However, 
after the event the causative agent of increased mortality can usually be regarded as 
resolved in survivors, therefore mortality after discharge is low. Hypothetically, translating this 
benefit to cardiac PMI identification and evidence based treatment of PMI might improve 
outcomes in cardiac PMI. 
Making use of hs-cTn preoperatively 
PMI appears to be reliably detected only with the use of systematic hs-cTn screening4, 
therefore measuring hs-cTn in the perioperative setting should be considered in routine 
clinical practise. The successful implementation of such a screening was an important step in 
showing that screening that includes preoperative measurements can be successfully 
implemented. To date, the screening has been conducted in >7000 cases at the University 
Hospital in Basel and was also successfully implemented in an external center, the 
Kantonsspital Aarau, where >1500 cases have been screened since its implementation in 
2016. We have published our internal standards to encourage more widespread use of PMI 
screening121. When implementing such a screening, it is important to make best use of the 
additional information provided by cTn, ideally preoperatively. Therefore we wished first to 
validate commonly used risk scores, especially the Lee score35,72, and then to combine the 
scores with the information gained from hs-cTn. In our study, the evaluated scores offered a 
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moderate discrimination between patients according to their risk, but severely 
underestimated the absolute risk, especially in the groups labelled “low-risk”. As we could not 
validate the scores, owing particularly to a lack of calibration of the scores predicting rates of 
up to ten-fold lower than observed, there is clearly a need to recalibrate established scores 
or to derive new risk scores. One attractive option for improving the predictive accuracy 
would be to use the prognostic value of preoperative hs-cTn, which was demonstrated in 
earlier studies31,41. We found that hs-cTnT and I were both useful in predicting all-cause 
death and postoperative MACE. As the prognostic value offered by hs-cTns appeared to be 
comparable or even superior to that of conventional risk scores, we believe that hs-cTn could 
be a valuable component of future preoperative risk stratification. The question of whether to 
use hs-cTnT or hs-cTnI depends, we believe, on the population, with hs-cTnI providing 
additional value in vascular surgery patients, as well as on the endpoint that should be 
predicted, with hs-cTnT potentially offering benefits in the prediction of all-cause mortality. 
Better assessment of the risk-benefit ratio of a surgical procedure is expected to help 
patients and physicians to make an informed decision on performing elective surgery in 
patients at high risk of MACE following non-cardiac surgery. Given the growing concern 
about unnecessary surgical operations performed in high-income countries such as 
Switzerland and the United States122, this could not only help to prevent major harm to 
patients, but might also reduce costs to the health care system; first by avoiding the cost of 
unnecessary surgery and secondly by avoiding costs related to MACE, including PMI 
following non-cardiac surgery. Better risk-stratification provided by new scores could help to 
base the medical and political decisions on which hospital should provide what medical 
service on a more insightful foundation. For instance, major non-cardiac surgery in patients 
at high risk of developing MACE following non-cardiac surgery should possibly be offered 
only at a small number of dedicated hospitals, while the same procedure in patients at much 
lower risk could well be justified in a regional hospital close to the patient’s home. 
Future directions of research 
The BASEL-PMI observational study is ongoing, having recruited over 8500 cases from two 
centres during the period of my PhD studies. The analyses presented in this thesis are the 
first major results from this study, with more analyses planned. Most important are the 
characterisation of PMI and the exploration of potential management strategies, as briefly 
discussed below. 
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Characterisation and pathophysiology of PMI 
One central and pre-specified analysis of our study will be to further explore PMI and 
evaluate predisposing comorbidities as well as perioperative factors contributing to PMI. As 
screening cohorts of patients seems to be necessary for detection, knowing which groups 
are particularly susceptible to developing PMI is essential to inform the choice of target 
population for a screening, e.g. patients with coronary artery disease, chronic kidney disease 
or diabetes7,46. 
Our knowledge of perioperative factors contributing to the occurrence of PMI is also limited. 
Without a clear identification of potentially modifiable contributors, it is currently difficult to 
implement preventive measures. In addition, identifying perioperative factors could further 
our understanding of the pathophysiology of PMI, which is believed to be a mix of injuries 
caused by plaque rupture (type I mechanism) and injuries caused by a supply-demand 
mismatch (type II mechanism)11,13,17. Our data should allow us to gain further insights into the 
presumed pathophysiology of PMI and potentially allow us to define further subtypes of 
cardiac PMI in particular.  
Management strategies for PMI 
The data generated in this study will be used to generate hypotheses for medical strategies 
to improve outcome after non-cardiac surgery. One example is the analysis of the effect of 
statins in the perioperative period. Multiple cardiovascular guidelines currently encourage the 
use of statins for prevention of adverse cardiac events for a wide range of diseases in the 
non-surgical setting84,123–125. Despite this established evidence of benefit in acute and chronic 
cardiovascular disease, the optimal perioperative use of statins remains unclear, partly as a 
result of controversy regarding the scientific integrity of several randomized clinical trials of 
perioperative statins126. Current perioperative guidelines addressing patients at 
cardiovascular risk undergoing non-cardiac surgery limit their recommendations to the 
continuation of an established statin therapy, and the potential initiation of therapy in patients 
undergoing vascular surgery25. This is based largely on two meta-analyses that found 
inconclusive evidence of the benefit of statins for prophylaxis of perioperative events127,128, 
except in patients undergoing vascular surgery. New data emerging from observational 
studies and a small randomized trial, however, have shown potentially beneficial effects of 
perioperative statins in reducing postoperative mortality and the incidence of PMI129,130. In 
addition, observational evidence indicates a potential benefit of statin therapy following the 
occurrence of a PMI6. Promising strategies are candidates for future investigator initiated 
clinical trials, which could be conducted within the established and still expanding study 
network of BASEL-PMI.  
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Contributions by the PhD student 
I was given the wonderful opportunity of being part of this study from its very onset and was 
able to contribute from the planning phase to the design and implementation, and finally to 
the analysis and writing up of this large observational study. In this nurturing environment, I 
was challenged and encouraged and played a substantial role in the development of the 
project plan, the study protocol and the ethics proposal and in the coordination of our study 
group, the implementation of the screening in the hospital and in the management of the 
growing BASEL-PMI on-site team.  
I performed a thorough literature review (from which a narrative review was created100), 
drafted the first version of the study protocol, including endpoint definitions, pre-specified 
analysis plans for our main and secondary objectives and sample size estimation and I 
coordinated our study group during the drafting process. I drafted and submitted the ethics 
proposal and funding proposals to the Swiss National Science Foundation, the Swiss Heart 
Foundation, the proPatient foundation, the PhD Education Platform for Health Sciences and 
the University Hospital Basel. During the course of the study, I drafted and submitted three 
ethics amendments to our study protocol; these were to allow an extension of the study 
beyond the initial 3000 patients, to include an external centre, and to apply for a sub-study 
concerning reuse of routine sample material.  
As study coordinator, I further developed the study infrastructure by selecting the study 
variables, creating and maintaining our study database and establishing contacts and 
interfaces with our clinical IT structure. I managed the data, conducted risk analyses and 
change management and wrote and curated the standard operating procedures. I also had a 
large part in the education of new study team members and conducted regular updates for 
the clinical teams, acting as a link between the clinical routine screening and our study team. 
As part of our research team, I was involved in supervision of MD candidates and Masters 
students, with an emphasis on imparting research methodology and statistics skills, but also 
co-supervising Masters and MD-theses towards the end of my studies. Furthermore, I was 
part of the methodological and statistical support for other studies, helping to draft grant 
proposals (APACE, BASEL-VIII, BASEL-IX), writing ethics proposals, as well as providing 
methodological input, conducting specific analyses, double checking statistical analyses (as 
is customary in our group) and providing critical and constructive feedback on manuscript 
drafts. In order to further our collaboration with external partners, I performed a database 
merge with a study team from Sao Paulo and conducted analyses on the shared data file. 
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I learned many important aspects concerning the analysis of data and the drafting of 
manuscripts during my time as PhD candidate, both directly from my supervisor and from the 
close collaboration with him and other excellent researchers from my group and from 
international experts. I drafted pre-specified analysis plans and did highly exploratory work, 
drafted, submitted and revised manuscripts as first and co-first author and presented our 
work at international, national and local conferences in the form of talks and posters. 
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Conclusion and closing remarks 
This PhD was the initial step in a concerted effort to improve perioperative care by 
generating essential knowledge on perioperative myocardial injury. In our observational 
study, which included nearly 3000 cases, we realised that PMI is very common after non-
cardiac surgery and is associated with high short-term and long-term mortality. This 
excessive mortality rate is independent of whether patients with PMI fulfil any of the 
additional criteria required for spontaneous acute myocardial infarction, such as ischemic 
symptoms. As the majority of patients do not exhibit any ischemic symptoms, systematic 
screening should be considered for accurate detection of PMI. As a result of this under-
detection, the incidence of PMI and therefore cardiac complications after non-cardiac surgery 
is currently underestimated and is not adequately represented in currently established risk 
scores. Increased awareness and consensus on a definition of PMI could to be important first 
steps towards improving perioperative care. This study provides important insights that will 
assist in achieving this goal. Future research concerning the detailed characterization of PMI 
and potential strategies to improve outcomes is necessary and are the planned next steps. 
 
“If I have seen further, it is by standing on the shoulders of giants.” – Sir Isaac Newton 
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